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ABSTRACT 
Uterine leiomyomas are benign neoplasms arising from smooth muscle cells of the uterus. They 
are clinically diagnosed in 25% of women and are associated with significant morbidity. Whole 
exome approaches have identified heterozygous somatic mutations in the mediator complex 
subunit 12 (MED12) in about 70% of leiomyomas with a majority harboring in exon 2 of MED12 
with c.131G>A being the most common SNV. MED12 protein is part of the large mediator 
complex and is involved in transcriptional regulation of RNA Polymerase II. To elucidate the role 
of MED12 exon 2 variants in leiomyomagenesis, we generated three different mouse models of 
Med12; loss-of-function, dominant-negative and gain-of-function mouse models.  
The loss-of-function females lacked any leiomyoma-like lesions, instead the reproductive 
tracts were hypoplastic and the females were infertile.  
We engineered a model where we conditionally floxed Med12 c.131G>A cDNA and 
inserted into the ROSA26 locus to generate Med12 ROSA knock-in mice. Amhr2-cre was used to 
drive the expression of the mutant Med12 from the ROSA locus either in the absence (gain-of-
function) or presence (dominant-negative) of X-chromosome wild-type Med12 in the uterine 
mesenchyme. Uteri from (gain-of-function) females displayed leiomyoma-like lesions in about 
87% of females. Similar characterization of uteri of dominant negative females revealed the 
development of leiomyoma-like lesions, but with appearance of smaller lesions and lower 
penetrance (50% of females) as compared to the gain-of-function model, leading us to conclude 
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that the Med12 exon 2 variants are likely to cause uterine leiomyomas via gain-of-function 
mechanism.  
Array comparative genomic hybridization (aCGH) of mouse tumors displayed genome 
wide aberrations, affecting general tumor pathways. Interestingly, several regions previously 
implicated in human leiomyomas were also shared by the mouse leiomyomas, revealing the 
similarities between human and mouse leiomyomas. This data suggests that Med12 exon 2 
mutations are precursors to genomic rearrangements leading to an unstable genome. The public 
health significance of this work includes the successful development of the first animal model for 
uterine leiomyomas, which will be an invaluable tool to understand the role of MED12 in 
leiomyoma genesis, as well as provide a unique platform to test targeted therapeutics as an 
alternative to hysterectomies. 
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1.0  INTRODUCTION 
1.1 UTERINE LEIOMYOMAS 
Uterine leiomyomas (fibroids or myomas) are benign neoplasms arising from the smooth muscle 
layer of the uterus. Leiomyomas are one of the most common gynecological tumors occurring in 
women, with a frequency of occurrence ranging from 20-50% of women of reproductive age (1). 
This number can be even as high as 77% as majority of leiomyomas maybe asymptomatic and 
hence go undiagnosed (2). They are clinically diagnosed in about 25% of women and depending 
on their location in the uterus may be classified as subserous, submucosal or intramural. Grossly, 
leiomyomas often appear to be smooth, spherical and firm and can be as large as 20 cm (3). 
Larger leiomyomas may undergo degenerative changes including hemorrhage (dark red), 
necrosis (demarcated by yellow regions), cystic changes or even calcification. The size, location 
and number of tumors in the uterus often, determines the presentation and intensity of symptoms. 
Leiomyomas requiring treatment are often associated symptoms such as dysmenorrhea (painful 
menstruation), menorrhagia (heavy menstrual bleeding), infertility, miscarriage, ascites, anemia 
and polycythemia (4-6). On the other hand, leiomyomas growing outside or in between uterine 
walls (subserous and intramural) are very common and can cause pelvic discomfort or may even 
pressurize surrounding organs (7). The recurrence, size and unclear etiology of leiomyomas 
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makes their management difficult, making hysterectomies the only available long-term treatment 
option for women with leiomyomas (8).  
1.1.1 Epidemiology and risk factors 
Leiomyomas are usually prevalent after menarche, peak during reproductive years and regress 
after menopause (9, 10). The evidence strongly suggests a strong link between ovarian steroids 
and tumor progression in women. Further, factors such as early menarche in women, increases 
the risk for leiomyomas, while late onset of menarche and longer duration of lactation decreases 
the risk respectively (11-14). One hypothesis suggests that early menarche could expose the 
uterus to longer duration of menstruation and hormones, thereby increasing the number of cell 
divisions and a higher chance of accumulation of mutations in the myometrium. On the other 
hand, later age of menarche and lactation reduces the risk to leiomyomas as the lifetime exposure 
of the uterus to cyclical changes decreases (11). 
Race and ethnicity differences also play a crucial role in determining the incidence, 
presentation and severity of uterine leiomyomas. Studies conducted on North American women 
have shown ~10% higher incidence and a younger age of diagnosis of leiomyomas in African-
American women as compared to Caucasian women (9, 15). African-American women also had 
higher uterine weight, larger and more number of leiomyomas causing more severe symptoms, 
ultimately leading to a younger age at hysterectomy (16, 17). The cause for this racial disparity 
in tumor incidence and presentation is not understood.  A few studies have attributed a difference 
in estrogen metabolism as a possible explanation for the disparity of leiomyoma presentation 
between the two races (18).  
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Sibling and other family studies have strongly indicated a genetic predisposition for 
leiomyomas (19). First-degree relatives of women with leiomyomas have a two time higher risk 
of developing leiomyomas in their lifetime. Other environmental and lifestyle factors may also 
influence the development and outcomes of these tumors. The risk of leiomyomas increases with 
factors such as obesity, caffeine, alcohol, diabetes and hypertension. Interestingly, smoking 
reduces the incidence of leiomyomas (12, 20-24). Few studies have indicated a link between 
vegetarian diet and overall better prognosis of uterine leiomyomas (25).  
Xenoestrogens are compounds with the capability of disrupting estrogenic functions by 
acting as an agonist or an antagonist (26). Few such xenoestrogens have also been associated 
with the development of leiomyomas. For example, DDT (dichlorodiphenyltricholoroethane) has 
been determined to be present at significantly higher levels in leiomyomas as compared to 
normal myometrium (27). DES (Diethylstilbestrol) is another such xenoestrogen that has been 
shown to cause leiomyomas both through in-vivo models (28) and human data (29). 
Larger cohort studies looking at environmental and lifestyle factors and their influence on 
tumorigenesis are required to have a deeper understanding of their contribution to disease 
progression. 
1.1.2 Diagnosis and treatment 
Leiomyomas can be diagnosed during a bimanual pelvic exam and are perceived by an enlarged, 
firm or an irregularly shaped uterus. The initial diagnosis is followed by either an 
ultrasonography, saline-infusion sonohysterography, or by magnetic resonance imaging (MRI) 
(30). Ultrasonography or ultrasound is a relatively cheap imaging technique that is most 
frequently used to carry out differential diagnosis on intramural or subserous leiomyomas, but is 
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inefficient in detecting the exact number or position of leiomyomas (31, 32). Saline-infusion 
sonography can be used to detect submucosal leiomyomas as this technique uses saline to distend 
the uterine cavity, therefore allowing more accurate information to be obtained from the mucosal 
lining of the uterus. The most robust of these techniques is the use of MRI for diagnosis of 
leiomyomas (31, 33). Although, more expensive than a trans-vaginal ultrasound, it provides 
more precise information on the number, position (subserous, intramural, submucosal) and the 
size of leiomyomas with a sensitivity to detect even 5mm lesions (Figure 1.1). Precise diagnostic 
information on the number, size and position of leiomyomas can be crucial for determining the 
treatment and management of the disease (34).  
Figure 1.1 MRI image of an intramural uterine leiomyoma 
(Reproduced from Khan et al., 2014)  (32) 
The management of the disease depends on the severity of symptoms, skills of the 
surgeon, reproductive age and decision of the patients. The kind of treatments currently available 
for leiomyomas includes, medical therapy, minimally invasive procedures and surgery (32). 
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Medical therapies include short-term treatments used to provide either symptomatic relief or 
maybe used as a preoperative measure. These treatments are usually not used in the long-term as 
they often have either long-term risks associated with them, or they lack evidence on the health 
risks posed by their long-term use. Patients for symptomatic relief are often prescribed 
nonsteroidal anti-inflammatory (NSAIDs) drugs (pain) or transexamic acid to control 
menorrhagia (32). Combined oral contraceptives, levonorgestrel-releasing intra-uterine devices 
(Mirena), aromatase inhibitors or gonadotropin-releasing hormone analogs (GnRHa) are 
currently used as a pre-operative adjunct. Estrogen and especially progesterone receptor 
modulators are gaining popularity as an effective treatment option to reduce myoma volumes and 
associated symptoms. Mifepristone (RU486) and Ulipristal acetate are two such examples of 
progesterone receptor modulators, which have been subjected to clinical trials and are now being 
used clinically as a pre-operative measure in both the U.S and Europe (35, 36).  
Surgical therapy is currently, the only long-term and gold standard treatment available for 
uterine leiomyomas. For women of prime reproductive age or with a desire for future 
pregnancies, myomectomy (open or minimally invasive) is usually performed (depending on the 
physician). In the recent years, minimally invasive techniques are providing women not only 
with the option of preserving their uterus and fertility, but also reduce morbidity and recovery 
time in comparison to open surgery (32). Minimally invasive techniques include, uterine artery 
embolization (UAE), Magnetic resonance-guided focused ultrasound surgery (MRgFUS) and 
combined sonography and radiofrequency therapy (VizAblate). UAE is an image-guided 
technique through which the blood to the leiomyomas is blocked resulting in their shrinking (37). 
MRgFUS is a method of thermal ablation using high intensity ultrasound waves for shrinking 
fibroids, but is not widely available to women. The newest of these techniques is using a 
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combination of sonography and radiofrequency waves for treatment of fibroids using a 
transcervical device (VizAblate) (38). Although these techniques are helpful, they are not 
effective in preventing recurrent fibroids. The only definitive solution to the treatment of fibroids 
is a hysterectomy, which is effective in permanently alleviating the symptoms and the fibroids 
themselves. Other than ending a women’s fertility, hysterectomy carries serious risks such as 
damage to the excretory system, pelvic abscess, hemorrhage during surgery or pulmonary 
embolism (39). Thus there is a dire necessity to understand the etiology of this disease and 
develop a model to help better understand the tumor process as well as develop drugs as a 
definitive solution as an alternative to hysterectomies.  
1.1.3 Histopathology and molecular characteristics 
Leiomyomas are composed of whorled, uniform, fusiform plump smooth muscle cells forming 
fascicles. The spindle-shaped cells have indistinct borders, with blunt elongated nuclei, finely 
dispersed chromatin and small nucleoli. Leiomyomas often consist of disorderly arranged 
smooth muscle fibers interspersed abundantly with extracellular matrix deposits (collagen, 
fibronectin, proteoglycan) (Figure 1.2). Hyaline fibrosis and edema are also quite common in 
leiomyomas (3). About 10% of leiomyomas pathologically vary and present as heterogeneous 
lesions, mimicking malignant aspects (Table 1.1). Although, the histology presentation 
resembles malignant lesions, they are clinically diagnosed to be benign and are managed similar 
to conventional leiomyomas (Figure 1.3) (40). 
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Figure 1.2 Histopathology of conventional leiomyomas 
(A) Normal myometrium showing arrangement of smooth muscle fibers. (B) Pathology of typical leiomyoma
lesion marked by fibrosis, disorganized nuclei and ECM deposits. Higher magnification of (A) and (B) are
shown respectively in (C) and (D). Scale bars= Scale Bars = 0.5μm (A, B), 100μm (C, D).
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Table 1.1 WHO based pathological classification of uterine leiomyoma variants. 
Leiomyoma variant Features 
Cellular Leiomyoma   Significantly increased cellularity compared to the surrounding medium
     Lack of nuclear atypia 
Infrequent mitotic figures 
Usually irregular borders mimicking invasion 
Atypical Leiomyoma               Focal occurrence of highly atypical cells in a conventional leiomyoma 
Infrequent mitotic figures 
Lipoleiomyoma   Presence of adipocytes in conventional leiomyoma 
Myxoid leiomyoma Smooth muscle cells separated by myxoid material 
         Lack of cytological atypia 
         Infrequent mitotic figures  
Epitheloid Leiomyoma   Epithelial-like appearance in tumor cells 
Intravenous  leiomyomas      Smooth muscle cells within vascular spaces outside a leiomyoma 
  Infrequent mitotic figure 
(Adapted from Oliva et al., 2014) (40) 
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Figure 1.3 Histopathological variants of uterine leiomyoma 
(A) Cellular leiomyoma. (B) Epithelioid  leiomyoma (C) Atypical leiomyomas (D) Myxoid leiomyomas. (E)
Mitotically active leiomyoma (F) Lipoleiomyomas. These images were reproduced from webpathology
(http://www.webpathology.com/case.asp?case=570)
1.2 GENESIS OF UTERINE LEIOMYOMAS 
Leiomyomas are known to arise from a single cell of the uterus (monoclonal in origin) i.e. each 
fibroid nodule consists of a single type of active X-allele, though independent nodules may have 
different active X alleles (41-44). The initiation of leiomyomas or leiomyomagenesis, involves 
transformation of a normal cell into a neoplastic myometrial cell, which may be influenced by 
genetic, epigenetic, hormonal or remodeling due to monthly cyclical changes. 
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1.2.1 Ovarian hormones and leiomyomagenesis  
A large body of literature and circumstantial evidence show an important role of ovarian 
hormones (estrogen and progesterone) in the development of leiomyomas. The regression of 
fibroids after menopause, and the dramatic changes in leiomyomas associated with hormonal 
changes during early pregnancy or postpartum, are compelling pieces of evidence supporting the 
role of estrogen and progesterone in leiomyomas (9, 10, 45, 46). The mechanisms through which 
ovarian hormones influence the growth of these tumors are not clearly understood but several 
hypotheses suggesting a role of these hormones in tumor initiation and progression exist. One 
such initiation theory suggests the role of estrogen and progesterone in increasing the 
proliferative activity of cells ultimately leading to the rapid accumulation of somatic mutations 
(47). Alternatively, underlying anomalies in normal myometrium may result in an enrichment of 
estrogen receptors and altered estrogen metabolism in leiomyomatous uteri compared to normal 
myometrium (48). Estrogen metabolism is also altered in leiomyomatous uteri (10) through 
reduced levels of 17β-hydroxysteroid dehydrogenase catalyzing estradiol to estrone conversion 
leading to estradiol accumulation, or increased levels of aromatase, catalyzing the conversion of 
androgens into estrogens (49-52). 
In-vivo graft models, where human fibroid tissues are placed under the kidney capsule in 
mice, have shown the importance of progesterone and its receptor, as grafted human fibroid 
tissues show proliferation, accumulation of extracellular matrix and cellular hypertrophy under 
the influence of exogenous progesterone (53). Based on its proliferative role during pregnancy, 
progesterone is more likely to have a function in clonal expansion of tumor cells. It may mediate 
these effects through progesterone receptor, effecting and regulating hundreds of genes (54). 
11 
Progesterone also prevents apoptosis by increasing the levels of BCL2 in the fibroid tissue 
thereby contributing further to growth and progression of the tumor (55). 
The effects of estrogen and progesterone are often mediated by growth factor such as 
Transforming growth factor-β (TGF-β), basic fibroblast growth factor (bFGF), insulin-like 
growth factor (IGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and 
vascular endothelial growth factor (VEGF) (56) and are often present at higher concentrations in 
leiomyomas as compared to normal myometrium (10). Each of the growth factors may contribute 
to different aspects of tumorigenesis including ECM expansion, angiogenesis or clonal 
proliferation of cells. For example: Increased TGF-β may promote cell proliferation and ECM 
production (57) whereas FGF promotes angiogenesis in leiomyomas and cell proliferation, 
ultimately leading to tumor growth (58). 
1.2.2 Myometrial stem cells and leiomyomagenesis 
In the last few years, there have been emerging reports about the role of stem cells/ progenitor 
cells from human myometrium as a source of origin for human leiomyomas (59). Both human 
and mouse myometrium generate stem cells via asymmetric division, which are capable of 
differentiating into mature smooth muscles cells under the influence of estrogen and 
progesterone. This process is responsible for myometrial regeneration in a normal uterus (59, 
60). In an event of a genetic alteration, a myometrial cell may transform into a fibroid stem cell. 
These fibroid stem cells proliferate continuously to then give rise to a leiomyoma (61). Fibroid 
stem cells lacking ER and PR, often require surrounding myometrial cells rich in ER, PR, and 
ligands to support self-renewal of fibroid stem cells in a paracrine manner (61, 62). Thus steroids 
not only influence development of leiomyomas directly but also influence them indirectly via 
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supporting stem cell renewal and tumor progression. Another hypothesis suggests the role of 
injuries such as hypoxia induced ischemic injury to play a role in initiation of tumors (63). In 
vitro data shows that the myometrial stem cells are capable of differentiating into mature smooth 
muscle cells under hypoxic conditions (64), which would suggest that the stem cells under 
hypoxic conditions may give rise to differentiated leiomyoma cells. As leiomyomas are believed 
to have stem cells of their own, in much lower percentage than normal myometrium, it is also 
possible that the hypoxic environment could possibly cause the myometrial stem cells to convert 
into fibroid stem cells and thus contribute to tumorigenesis (61). 
1.3 GENETICS OF LEIOMYOMAS 
The etiology of fibroids has long been elusive. Twin studies, familial studies and hereditary 
syndromes have suggested a strong genetic component involved in leiomyomagenesis. In the 
past years cytogenetic analysis using classical karyotyping methods have shown 40-50% of 
tumors having tumor specific chromosomal aberrations such as inversions, deletions, duplication 
and translocations (65, 66). Though chromosomal aberrations and the inherited syndromes 
account for a fraction of leiomyomas, the genetic basis for the majority of leiomyomas remains 
unexplained. In this section I will discuss in detail the advances in understanding the molecular 
genetics and cytogenetics of leiomyomas using next generation sequencing technologies. 
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1.3.1 Cytogenetics of leiomyomas 
Chromosomal aberrations in uterine leiomyomas often associate with larger size tumors and are 
specific to the location of the tumor (67, 68). For example, the tumor size of leiomyomas with 7q 
deletions is much smaller in size compared to the size of tumors with 12q14 rearrangements (69). 
Similarly, intramural and subserous leiomyomas display more chromosomal aberrations than 
submucous leiomyomas (70).  
1.3.1.1   12q14-15 translocations 
About 20% of uterine leiomyomas display 12q14-15 rearrangements, making it one of the most 
common karyotypic abnormalities in these tumors (70). The 12q14-15 rearrangements, mostly 
occur as a simple translocation, t(12;14)(q15;q23-24) but can have other complex 
rearrangements (71-77).  Rearrangements in other benign mesenchymal tumors, such as 
angiomyxomas, breast fibroadenomas, endometrial polyps, hemangiopericytomas, lipomas, 
pulmonary chondroid hamartomas, and salivary gland adenomas, also have shown the 
importance of this region in tumorigenesis (78). The 12q breakpoint in uterine leiomyomas maps 
to a region identified as an evolutionarily conserved, high mobility group AT-hook 2 (HMGA2) 
gene, belonging to the high-mobility group A (HMGA) protein family (79, 80). The HMGA 
group of proteins are both positive and negative transcriptional regulators of genes. They 
indirectly regulate gene expression by bringing about conformational changes in the DNA and 
influencing the accessibility of DNA binding proteins (81). They play a role in diverse processes 
such as proliferation, differentiation, growth, and apoptosis (82, 83). HMGA2 protein is 
abundant and expressed ubiquitously during embryonic development, but is almost undetectable 
in adult tissues, except in the lungs and the kidneys (84-86). A majority of chromosome 12 
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breakpoints, in uterine leiomyomas, carrying t(12;14)(q15;q23-24)  map to the 5’ region of 
HMGA2 and a minority map to the 3’ region, suggesting impaired HMGA2 expression (75, 87). 
This may explain the aberrant overexpression of HMGA2 in leiomyomas (84, 88). It is possible 
that the translocation may either disrupt regulatory elements or place the gene near an effective 
promoter causing the aberrant expression. Let7-miRNAs directly regulate HMGA2 by binding to 
the 3’ UTR region and inhibiting HMGA2 expression. Removal of HMGA2 3’ binding site may 
provide another mechanism of HMGA2 overexpression (88-91). There is also a positive 
correlation between larger tumor sizes and the presence of t(12;14)(q15;q23-24), HMGA2 
overexpression and low expression let-7 miRNA (68, 90, 92). Evidence also supports the notion 
that overexpression of HMGA2 may be important for proliferation and maintenance of the 
transformed state of the cell (78). 
 The breakpoints on chromosome 14 involved in t(12;14)(q15;q23-24) in leiomyoma were 
mapped to identify the genes in this region (70, 93, 94). RAD51 paralog B (RAD51B) at the 
14q23~q24 emerged as a strong candidate translocation partner for HMGA2 (95, 96). RAD51B 
plays an essential role in homologous recombination mediated DNA damage repair (97). 
HMGA2 and RAD51B fusion transcripts occur in a small percentage of leiomyomas, but the 
underlying pathogenesis of majority of t(12;14)(q15;q23-24) is not understood (96, 98).  
In some leiomyomas, aberrant expression of HMGA2 may occur without the 12q14-15 
rearrangements (99), suggesting an independent role in leiomyoma pathogenesis (75). 
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1.3.1.2 Deletions of 7q 
Interstitial deletions of chromosome 7, del(7)(q22-32), occurs in about 17% of karyotypically 
abnormal leiomyomas (78). The deletions on the long arm of chromosome 7 have been narrowed 
down to the 7q22 band and are somewhat specific to uterine leiomyomas as compared to other 
solid tumors. The frequent LOH indicates the presence of tumor suppressor genes in this region 
(100-104). The identification of the target sequences in this region has been a challenge due to 
the dense cluster of genes in this region. CUX1 (cut-like homeobox 1) has been identified as one 
of the candidate tumor suppressor genes in this region, with diverse roles in cell proliferation, 
cell motility/invasiveness, and apoptosis (105, 106). This gene has also been identified as a 
frequent target in myeloid neoplasms (107, 108). Few other candidate genes in the 7q22 such as 
ORC5L, PCOLCE, and ZNHIT1 in the 7q22 region have also been identified in uterine 
leiomyomas; yet fail to consistently be in leiomyomagenesis (91, 109-111). The 7q deletions 
may either occur independently or sometimes co-exist with t(12;14) rearrangements in some 
leiomyomas (112). Cells from such leiomyomas persist in culture, compared to leiomyoma cells 
with 7q deletions as the sole cytogenetic anomaly (113). This may indicate the role of 7q 
deletions as a secondary cytogenetic change necessary for the progression of leiomyomas. 
1.3.1.3 6p21 rearrangements 
Rearrangements of 6p21 locus recurrently occur in a variety of benign mesenchymal tumors, 
such as lipomas, pulmonary chondroid hamartomas, and endometrial polyps (78). The 6p21 
rearrangements also occur in uterine leiomyomas with a frequency of <5%, with the majority of 
the rearrangements consisting of translocations and inversions (114-117). The high mobility 
group AT-hook 1 (HMGA1) gene has been identified as one of the targets of rearrangements at 
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the 6p21 locus (118, 119). Breakpoints on HMGA1 have also been demonstrated in pulmonary 
chondroid hamartomas and hamartomas of the breast (120, 121). The HMGA1 gene encodes a 
protein belonging to the HMGA family and also acts as a transcriptional regulator (71). 
Although, HMGA1 and HMGA2 belong to the same protein family, and have sequence and 
structural similarities but correlate with a substantially different expression pattern and 
phenotypic outcome, suggesting different functional roles of HMGA1 from HMGA2. For 
example, in uterine leiomyomas the relative overexpression of HMGA2 is more than HMGA1 
(78). Also, HMGA1 overexpression usually correlates with a more malignant outcome as 
observed in other epithelial tumors and leukemia (122). 
1.3.1.4  Other cytogenetic aberrations 
Trisomy of chromosome 12 affects about 10% of karyotypically abnormal leiomyomas (123). 
This may result in a copy number gain of HMGA2 resulting in overexpression of HMGA2 in 
leiomyomas (78). Other chromosomal aberrations such as deletion 10q, disrupting the K(lysine) 
acetyltransferase 6B (KAT6B) gene (124) or aberrations on chromosome 1,3, 13 and X also occur 
in uterine leiomyomas, but at a much lower frequency (78). These aberrations often occur with 
other cytogenetic rearrangements, indicating as a secondary change, acquired during multi-step 
tumorigenic process. The presence of multiple aberrations in individual tumors may also be 
suggestive of genomic instability in uterine leiomyomas. 
1.3.1.5 Monoclonality of leiomyomas 
Analyses of multiple tumors from a single uterus often display different cytogenetic aberrations 
across different tumors, suggesting the independent origins of each tumor (125). The process of 
lyonization or X-chromosome inactivation is where either of the X allele is inactivated in all 
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female somatic cells during embryonic development (126). The same X-inactivated allele is 
maintained throughout the lifecycle of a cell and is accordingly passed on to daughter cells. The 
process of X-chromosome inactivation has been used to study the clonality of leiomyomas. 
Tumors are monoclonal if they have the same X-allele inactivated in all of its cells, whereas 
polyclonal tumors arise from a mixture of cells. X-inactivation studies in leiomyomas have been 
carried out using various approaches, including glucose-6- phosphate dehydrogenase iso-
enzyme, X-linked androgen receptor CAG- repeats polymorphism, or phosphor-glycerokinase 
(PGK). All of the approaches have shown that independent leiomyomas in a uterus arise from a 
single cell, where independent tumors in the same uterus, exclusively have either of X-alleles 
inactivated (41, 43, 44, 127). 
1.3.1.6 Copy number alterations and gene expression profiling in leiomyomas 
Classical cytogenetics has been used for a long time to detect chromosomal aberrations in 
leiomyomas, but with the advent of newer technologies such as array comparative genomic 
hybridization (CGH), the genomic landscape can be analyzed at a much higher resolution. The 
array CGH technology allows the detection of submicroscopic copy number gains and losses, 
which were not previously, detected using standard karyotyping (G-banding) techniques. Few 
studies using array CGH have been conducted on leiomyomas and have shown additional copy 
number gains and losses including gains in chromosomes 9q and 19 and losses in chromosome 
22q. These gains and losses were present in addition to the classically detected aberrations but 
also did not commonly occur in leiomyomas (128-131). 
Series of gene expression microarray studies were also conducted on leiomyomas and 
normal myometrium to potentially identify differentially regulated genes and associated 
pathways in leiomyomas. Though the expression profiles were variable, genes involved in cell 
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proliferation, extra cellular remodeling, retinoic acid metabolism and apoptosis have been linked 
with leiomyomagenesis. Few examples of relevant genes include ADH1, 30 EGR1, C-FOS, 
IGF2, and TGFBR2. The results from these studies were often inconsistent, and failed to indicate 
any causal genes associated with tumorigenesis. The inconsistencies in the results could have 
been due to differences in microarray techniques, data analysis methods, ethnicity differences, or 
the genetic status of leiomyoma samples.   
Therefore, determining and validating novel genes associated with the initiation and 
progression of leiomyomas is key to developing successful therapeutic strategies against uterine 
leiomyomas. 
1.3.2 Leiomyomas and associated syndromes 
Hereditary cancer syndromes such as hereditary leiomyomatosis and RCC (HLRCC), tuberous 
sclerosis complex (TSC), and Birt-Hogg-Dube ́ (BHD) syndromes also predispose patients for 
developing leiomyomas, implicating a role of genes such as fumarate hydratase (FH), Tuberous 
sclerosis 2 (TSC2) and Birt-Hogg-Dube ́ (BHD) in a small subset of leiomyomas.  
1.3.2.1 Hereditary leiomyomatosis and renal cell cancer (HLRCC) 
Hereditary leiomyomatosis and renal cell cancer (HLRCC; MIM 150800, HLRCC; Gene 
Reviews), also known as multiple cutaneous and uterine leiomyomatosis (MCUL), is a rare 
disorder, with a dominant pattern of inheritance. Only about 100 families around the world are 
reported to have this condition. Individuals tend to develop benign tumors such as cutaneous and 
uterine leiomyomas and are at high risk of developing renal cell cancer (132). Cutaneous 
leiomyomas are benign neoplasms arising from the muscles surrounding hair follicles. Cutaneous 
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lesions may grow as bumps throughout the trunks and limbs, and are sensitive to touch or 
temperature and maybe painful (133). Affected women also develop multiple large uterine 
leiomyomas, with severe symptoms and an earlier age of onset as compared to the general 
population (134). Only about 10-16% of women with this disorder develop renal cell cancer 
(132, 133, 135, 136) but the malignant lesions are often very aggressive and can metastasize very 
quickly making diagnosis and management of cancer very difficult. 
 HLRCC is primarily caused due to heterozygous germline mutations in FH located on 
chromosome 1(1q42) (137). FH gene encodes fumarase or fumarate hydratase, an enzyme 
catalyzing the conversion of fumarate to malate in the tricarboxylic acid cycle (TCA cycle), 
important for generation of energy in the mitochondria.  Germline mutations in FH gene may 
occur as heterozygous missense (~58%), nonsense (~11%), or frameshift mutations (~18%) 
(133, 138). A second hit or bialleleic inactivation of FH mostly occurs due to loss of 
heterozygosity events triggered by environmental factors, but may rarely be caused by a second 
point mutation (132, 139). It is thought that the biallelic inactivation of FH may render fumarase 
inactive, causing a buildup of fumarate or succinate in the cell (140). Excessive fumarate 
stabilizes the HIF1 creating a   “pseudohypoxic” condition (141, 142). HIF1 in turn regulates 
genes responsible for vascularization, glycolysis, and glucose transport, contributing to 
tumorigenesis. Only about 1.3% of FH mutations contribute to leiomyoma pathogenesis (143-
145). 
1.3.2.2  Leiomyomas associated with other syndromes 
Uterine leiomyomas may also be associated with hereditary syndromes such as Tuberous 
sclerosis complex, Birt-Hogg-Dubé (BHD), and Cowden syndrome. TSC is a multi- organ rare 
dominant disorder caused due to heterozygous germline mutations in the TSC1 or TSC2 genes 
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located on chromosome 16 (146). The Eker rat, an animal model for the TSC, carrying 
heterozygous TSC2 mutations have shown spontaneous incidence of uterine leiomyomas (147, 
148). The details of this model will be further discussed in section 1.3.6. Similarly, German 
Shepherd canine models for Birt-Hogg-Dubé syndrome, carrying germline mutations in Bhd 
gene also spontaneously develop leiomyomas (149). Cowden syndrome is caused due to 
germline mutations in PTEN tumor suppressor gene resulting in multiple benign growth or 
hamartomas (150). About 50% of these patients also develop uterine leiomyomas (151). These 
syndromes although genetically associated with leiomyomas, only explain the etiology for a very 
small fraction of leiomyomas.  
1.3.3 Molecular genetics of leiomyomas 
1.3.3.1 Genome wide association studies 
In the past two decades, twin studies and familial aggregation studies have suggested a strong 
genetic component in the occurrence of leiomyomas. Genome wide association studies have 
revealed three chromosomal loci (10q24.33, 22q13.1, and 11p15.5) associated with incidence of 
leiomyomas in Japanese women (152). These findings could not be consistently replicated across 
various other ethnicities (153-155). Another genome wide association study conducted on a 
cohort of European Caucasian women, suggested a novel risk allele on chromosome 17q25.3, 
coding for fatty acid synthase (FASN) (153).  Supporting this evidence, the expression level of 
fatty acid synthase was significantly higher in leiomyomas as compared to surrounding 
myometrium. Previously, fatty acid synthase has been associated with other tumors and has been 
known to promote tumorigenesis (156-158). These associations are still pending confirmation. 
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1.3.3.2 Whole exome sequencing; MED12 exon 2 variants and leiomyomas 
In the past five years, the rapid advancement of next generation sequencing (NGS) has 
revolutionized the field of cancer genomics, allowing us to discover and explore previously 
unknown somatic alterations such as point mutations, indels (insertion and deletions) in tumor 
pathogenesis. Others and we have utilized whole exome technologies to identify novel somatic 
candidate drivers associated with uterine leiomyomas to improve our understanding of genetics 
underlying the development of tumors.  
The first whole exome sequencing studies were conducted on 18 uterine leiomyomas 
from 17 Finnish women (Finnish population) (159). Upon analysis, MED12 was identified as the 
only recurrently mutated tumor specific gene. All of the identified mutations were heterozygous 
and were located in the exon 2 of MED12, with majority of the single nucleotide variants 
occurring specifically in codon 44 of exon 2. To verify the MED12 exon 2 variants, Sanger 
sequencing was performed on the initial eighteen leiomyomas, and an additional 207 
leiomyomas. The results revealed about 70% (159/225) of leiomyomas harboring MED12 exon 2 
mutations. About 70% of the MED12 exon 2 variants were located in codon 44 including all six 
base pair substitutions. The most common non-synonymous missense variant was a c.131G>A 
causing a glycine (G) to aspartic acid (D) amino acid change (pG44D) (159). The glycine on 
codon 44 is conserved across 39 different species including plants and fungi (one of the most 
conserved residues). Other MED12 mutations were observed in codons 36 and 43 of exon 2. 
Indels were also observed in 15% of MED12 mutated leiomyomas. Mutant MED12 allele 
expression (active X) was also confirmed in the cDNA of all leiomyomas.  
MED12 positive mutation status also correlated with smaller tumor sizes and gene 
expression profiling of MED12 positive leiomyomas showed unique clustering of genes affecting 
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focal adhesion, ECM receptor and Wnt signaling pathways. Makinen and colleagues also 
confirmed the presence of 50% MED12 exon 2 heterozygous variants in leiomyomas from 
women of another ethnic background (South African), although the sample sizes were small 
(160).  
We conducted whole exome sequencing in parallel to the Finnish group, and performed 
targeted sequencing studies on 148 leiomyomas from mixed cohort of North American women 
(120 white American and 23 Black American).  We also discovered novel MED12 exon 2 
heterozygous variants in 70% (100/148) of leiomyomas and none in the normal myometrium 
(161). Similar to Makinen et al., studies published from our lab showed 68 out 76-missense 
variant occurring at positions 130 and 131 in the 44th codon, exon 2 of MED12 (Table 1.2). 
Remarkably, in our study as well, the most commonly observed non-synonymous single 
nucleotide variant was the c.131G>A, p. G44D, heterozygous variant (Figure 1.4). Higher 
frequency of MED12 mutations correlated with the presence of multiple tumors per uterus as 
opposed to a single tumor. MED12 exon 2 variants were detected in leiomyomas from both white 
American and African American women (66% and 78% respectively), suggesting a universal 
role of MED12 exon 2 variants in leiomyoma pathogenesis regardless of ethnicity or race. 
MED12 mutation status was also equally distributed among, karyotypically normal and abnormal 
leiomyomas and therefore we could not conclude if the MED12 mutations are true precursors to 
cytogenetic alterations (161).  
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Figure 1.4 MED12 exon 2 variants associated with uterine leiomyomas 
Illustration of all 45 coding exons of the MED12 gene. The asterisk denotes the mutations determined in exon 2 of 
MED12 in leiomyomas from North American women. 71% of these non-synonymous variants occurred in codon 44 
of exon 2 affecting the Glycine residue. The most common missense variant was c.131G>A variant causing a 
glycine to aspartic amino acid change. 
(Figure has been reproduced from McGuire at al., 2012) (161) 
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Table 1.2 List of missense, splice-site variants and indels in exon 2 of MED12 
(Table reproduced from McGuire et al., 2012) (161) 
a The number of leiomyomas with each variant is followed in parentheses by the percentage of the total number of 
leiomyomas under study (148) and the percentage of the total number of mutated leiomyomas (100), respectively. 
Multiple groups have now validated and replicated the presence of MED12 exon 2 mutations, in 
leiomyomas from ethnically diverse women including German, Korean, Japanese, Dutch and 
Hispanic cohorts (162-174). The MED12 mutation rates ranged from 50% to 80%, which may 
Variant type Nucleotide change Protein change Number of mutated 
leiomyomasa 
Missense c.107T>G p.L36R 3 (2.0% / 3.0%) 
(Exon 2) c.128A>C p.Q43P 5 (3.4% / 5.0%) 
c.130G>C p.G44R 7 (4.7% / 7.0%) 
c.130G>A p.G44S 9 (6.1% / 9.0%) 
c.130G>T p.G44C 8 (5.4% / 8.0%) 
c.131G>C p.G44A 5 (3.4% / 5.0%) 
c.131G>A p.G44D 32 (21.6% / 32.0%) 
c.131G>T p.G44V 9 (6.1% / 9.0%) 
c.130G>T; c.131G>T p.G44F 1 (0.7% / 1.0%) 
Splice Site IVS1-8T>A p.E33_D34insPQ 2 (1.4% / 2.0%) 
(Intron1-Exon2) IVS1-1_139del41 Lose splice acceptor 1 (0.7% / 1.0%) 
IVS1-2_141del44insAG Lose splice acceptor 1 (0.7% / 1.0%) 
Deletions c.103_138del36 p.E35_N46del 1 (0.7% / 1.0%) 
(Exon 2) c.107_111del5insGC p.L36_T37delinsR 1 (0.7% / 1.0%) 
c.111_155del45 p.A38_S52del 1 (0.7% / 1.0%) 
c.113_121del9 p.A38_N40del 1 (0.7% / 1.0%) 
c.117_122del6 p.N40_V41del 1 (0.7% / 1.0%) 
c.118_132del15 p.N40_G44del 1 (0.7% / 1.0%) 
c.118_134del17insTA p.N40_F45delinsY 1 (0.7% / 1.0%) 
c.118_146del29insTT p.N40_P49delinsF 1 (0.7% / 1.0%) 
c.122_148del27 p.V41_P49del 1 (0.7% / 1.0%) 
c.122_163del42 p.V41_D54del 1 (0.7% / 1.0%) 
c.123_152del30 p.K42_V51del 1 (0.7% / 1.0%) 
c.126_131del6 p.K42_G44delinsN 1 (0.7% / 1.0%) 
c.126_140del15 p.K42_F45del 1 (0.7% / 1.0%) 
c.129_137del9 p.Q43_N46delinsH 1 (0.7% / 1.0%) 
c.129_143del15 p.G44_Q48del 1 (0.7% / 1.0%) 
c.133_144del12 p.F45_Q48del 1 (0.7% / 1.0%) 
c.149_163del15 p.A50_D54del 1 (0.7% / 1.0%) 
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vary due to location or the size of leiomyomas analyzed. Rarely, somatic MED12 exon 1 
mutations consisting of in-frame insertion-deletions have been reported in a few MED12 exon 2 
negative leiomyomas (175). Yet, the majority of the MED12 mutations occur as hotspot 
mutations in exon 2 of the MED12 gene, underlying their significance in the development of 
uterine leiomyomas.  
  Majority of MED12 mutations seem to occur only in conventional leiomyomas, with rare 
clinical histological subtypes including cellular leiomyomas, HLRRC leiomyomas and 
leiomyomas with bizarre nuclei, harboring only 5-17% of MED12 exon 2 mutations (168, 176). 
Mitotically active leiomyomas had MED12 mutation rates (38%) very similar to that of 
conventional leiomyomas.  About half of the MED12 variants occurring in the histopathological 
leiomyoma variants were in codon 44 of exon 2 of MED12, signifying the importance of this 
codon in leiomyoma pathogenesis irrespective of the clinical sub-type. Interestingly, leiomyomas 
from HLRCC patients showed that MED12 mutations and biallelic loss of FH were mutually 
exclusive events (173, 176). 
1.3.3.3 MED12 mutations and genomic alterations 
Whole genome sequencing provides the most comprehensive sequence data on the genome 
including coding and non-coding genetic variation, copy-number alterations, and structural 
rearrangements (177). Mehine and colleagues performed whole genome sequencing on 38 
uterine leiomyomas including sixteen MED12 positive leiomyomas, four FH deficient 
leiomyomas, and eighteen leiomyomas lacking MED12 and FH mutations (91). The study found 
no new recurrently mutated somatic point mutations but found typical cytogenetic alterations 
associated with leiomyomas such as t(12;14)(q15;q24) and deletions in  chromosome 7q. The 
genome of leiomyomas lacked any large amplified segments (<100 kb) or high-level genomic 
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amplifications, suggesting a mechanism protecting the genome from malignant degeneration 
(91). The most interesting finding was the common occurrence of complex chromosomal 
rearrangements called chromothripsis in both MED12 positive (3/16) and MED12 negative 
leiomyomas (12/16) (91, 178). Chromothripsis is defined as a single genetic event leading to 
shattering and random reassembly of an entire chromosome (179). 
To determine if the recurrent MED12 mutations synergistically acted with other 
cytogenetic alterations, Markowski et al., investigated the association of MED12 mutations in 
leiomyomas with specific recurrent cytogenetic alterations. The findings of the study showed 
that the MED12 mutations and frequent cytogenetic alterations such as the deletion of long arm 
of chromosome 7 and the 6p21 rearrangements coexist (163). This would suggest that the 
MED12 mutations are precursors to some of these genetic alterations and the observed 
cytogenetic changes may be more of a secondary change, occurring during the course of disease 
progression. Interestingly, multiple studies have highlighted a clear distinction between MED12 
mutated leiomyomas and leiomyomas with HMGA2 rearrangements, signifying different 
pathways of MED12 mutated and HMGA2 mediated leiomyomagenesis (91, 172). It is quite 
fascinating to note that MED12 mutations and HMGA2 rearrangements could possibly explain 
85% of the cases. 
Based on gene expression analysis, several reports have suggested that MED12 mutations 
have a unique effect on global transcription patterns. Makinen et al., showed the effect of 
MED12 mutations on pathways associated with focal adhesion, extra cellular matrix remodeling, 
and WNT signaling pathways (159). Markowski et al., investigated the expression of WNT4, as it 
is present in the mesenchyme and is also located at the chromosomal locus, which is altered in 
leiomyomas (1p36). Analysis of WNT4 in leiomyomas with MED12 mutations showed higher 
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expression compared to HMGA2 rearranged leiomyomas or normal myometrium, thus justifying 
its role as a probable target and mediator of MED12 for affecting WNT signaling in the 
myometrium (163). Gene expression studies conducted by Mehine et al., have also shown 
RAD51B, a DNA repair gene, also to be up-regulated in leiomyomas, implicating oncogenic 
stress in the smooth muscle cells possibly caused by MED12 mutations (91). 
1.3.3.4 MED12 mutations in other benign and malignant tumors 
Ever since the discovery of recurrent MED12 exon 2 mutations in uterine leiomyomas, series of 
investigations have been conducted to detect the presence of MED12 mutations in a host of other 
benign and malignant tumor types. To begin with, the frequency of MED12 exon 2 variants was 
examined in malignant counterparts of leiomyomas; i.e. leiomyosarcomas. Uterine 
leiomyosarcomas are clinically rare, aggressive, highly recurrent tumors with poor prognosis and 
survival (176-178, 180). Reports addressing the origins of leiomyosarcomas are often 
contradictory; with some reports indicating a de novo event versus others indicating MED12 
altered precursor leiomyomas as the underlying cause (181-184). Recurrent MED12 exon 2 
variants were discovered only in a limited number of leiomyosarcomas (5-20%), suggesting a 
different pathway of pathogenesis as compared to MED12 positive leiomyomas (162, 164-167, 
169, 172, 185). Smooth muscle tumors with uncertain malignant potential (STUMP) are a group 
of heterogeneous tumors, with an uncertain benign or malignant pathological diagnosis. MED12 
exon 2 variants were determined in STUMPs also with a low frequency (11%) (164). Strikingly 
MED12 expression was found to be undetectable in a majority of leiomyosarcomas and 
STUMPs, including leiomyosarcomas harboring MED12 exon 2 variants. Contrary to the 
malignant tumors, MED12 mutated leiomyomas, expressed MED12 irrespective of the MED12 
mutation status (164, 167, 172). This suggests that MED12 variants are more common in benign 
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tumors than their malignant counterparts, and the MED12 exon 2 variants may exert completely 
different effects in benign versus malignant tumors. 
Other than human leiomyomas, MED12 exon 2 variants have recently been discovered as 
the sole recurrent mutations in other benign tumors such as fibroadenomas and phyllodes tumors 
of the breast. Remarkably, the MED12 mutation rates in these tumors were very similar to that of 
uterine leiomyomas, with 59% of fibroadenomas (186) and 80% of phyllodes tumors harboring 
the MED12 exon 2 variants, suggesting common mechanisms of pathogenesis (187-190). 
Interestingly, MED12 c.131G>A was again the most common missense variant discovered in 
these tumors as well (186, 187). This suggests a very specific role of the MED12 exon 2 variants 
in steroid-driven benign tumors in females. 
MED12 exon 2 variants have been rarely described in few carcinomas such as colon 
carcinomas (0.3-0.5%) (162, 185), basal triple-negative carcinomas (191) and chronic lymphatic 
leukemias (<1%) (CLL) (192). Other than MED12 exon 2 variants, somatic mutations have also 
been observed in other regions of MED12 gene, in hormone related prostate and adrenocortical 
carcinomas (193, 194), but the pattern of these variants are slightly different from the exon 2 
variants, indicating distinct pathways of MED12 between malignant and benign tumors. 
Nonetheless, the high recurrence rate of MED12 exon 2 variants in uterine leiomyomas, 
fibroadenomas, and phyllodes tumors highlights the importance of understanding the role of 
MED12 variants in tumorigenesis.  
1.3.4  MED12 germline mutations 
Prior to the association of MED12 with uterine leiomyomas, germline mutations in the C-
terminus of MED12 have been linked with three X-linked mental retardation syndromes; namely 
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Opitz Kaveggia syndrome (MIM 305450) (195, 196), Lujan-Fryns syndrome (MIM 309520) 
(197), and Ohdo syndrome (Maat-Klevit-Brunner type) (198). All of the above syndromes occur 
in an X-linked recessive fashion, mostly affecting males and have missense mutations in the 
leucine-serine-rich (LS) domain of MED12. For example, MED12 c.2881C>T, c.3020A>G 
missense variants are associated with Lujan-Fryns syndrome, c.5185 C>A is associated with 
Ohdo syndrome, and c.2873 G>A is associated with Opitz Kaveggia syndrome (195-198). 
Patients with these syndromes often exhibit intellectual disability (mild to severe), behavioral 
problems, dysmorphic facial features and hypotonia. There have been no reports describing 
uterine leiomyomas in patients with these syndromes. Contrary to somatic MED12 exon 2 
variants associated with leiomyomas, C-terminal germline MED12 variants are extremely rare 
and are believed to have very different molecular pathogenesis. It is hypothesized that the 
germline MED12 mutations may affect REST-imposed epigenetic silencing of neuronal gene 
expression by disrupting mediator and RE1- silencing elements causing the rare mental 
retardation syndromes (198, 199). 
1.3.5 Mediator complex subunit 12 (MED12) 
The MED12 gene is located on X chromosome (Xq13) and consists of 45 exons, encoding a 
250kDa protein (2177 amino acids) (191, 196). The MED12 protein is highly conserved amongst 
eukaryotes, specifically in mammals (200). The protein is divided into four domains based on 
sequence similarity: a leucine-rich (L), leucine-serine-rich (LS), proline-glutamine-leucine-rich 
(PQL), and an odd-paired (Opa) domain, though not much is known about the function of each 
domain. MED12 has ubiquitous expression in adult human tissues, but has higher expression 
during fetal development (201, 202). 
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Figure 1.5 MED12 as part of the CDK8 kinase module in the mediator complex 
Schematic representation of the mediator complex subunits (denoted by different colors) and the RNA pol II 
transcriptional machinery. The core mediator consists of the head (blue), middle (green), tail (purple) and the kinase 
module (orange). MED12 is part of the CDK8 sub-complex (orange) and reversibly associates with the core 
mediator complex. The mediator complex acts as a bridge between DNA regulatory elements and the transcriptional 
machinery. Components present only in higher eukaryotes are denoted by asterisk.  
(Reproduced from Larivière et al., Science Direct 2012; with copyright permission from Elsevier, 2015) (203). 
MED12 is a part of a large complex of mediator proteins and is involved in 
transcriptional regulation of RNA polymerase II complex in eukaryotic cells (204, 205). The 
mediator complex acts as an intermediate between transcription factors and RNA Pol II and 
relays regulatory information from transcription factors to RNA Pol II, which is an essential step 
during initiation and elongation process of transcription (202-204). The structure of the Mediator 
complex consists of head, middle, tail sub-complexes and a separate kinase (CDK8) sub-
complex. The head and the middle sub-complex bind to Pol II, whereas the tail sub-complex 
binds to other transcription factors and undergoes conformational changes to form the “foot” or 
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the “hook” domain respectively (204, 206, 207). The kinase sub-complex reversibly associates 
with the mediator complex and brings about large structural changes to the core mediator 
complex (Figure 1.5) (203, 208). When the kinase sub-complex disassociates from the core sub-
complex, head and the middle mediator sub-complex binds to RNA Pol II whereas the tail sub-
complex binds to transcription factors or co-activators, leading to highly efficient transcription in 
the cells (207, 208). To render the complex inactive, kinase sub-complex attaches itself to the 
core sub-complex, bringing about structural changes such that it allosterically inhibits the 
interaction of the core mediator and RNA Pol II, thereby inhibiting transcription (209). It is 
believed that the mediator complex can carry out gene specific transcription based on its 
interaction with specific co-regulatory transcription factors, which in turn would mediate its 
effect through cell specific targets in the mediator (204). Given the large structure and the 
complexities of the mediator complex, its role in cell specific gene regulation is not clearly 
understood. 
The kinase sub-complex consists of MED12, MED13, CDK8, and Cyclin C as its 
subunits, which can act as a transcriptional activator or repressor of gene transcription (206, 
210). The kinase sub-complex can also phosphorylate the C-terminus of the Pol II subunit, 
thereby affecting transcription carried out by the RNA Pol II complex (209). The kinase module 
“hooks” onto the core mediator complex via MED13 (211). MED12 is also essential in the kinase 
module for the kinase activity of CDK8, but MED12 can carry out functions independent of 
CDK8 kinase (212). MED12 has been shown to interact with a variety of pathways including 
WNT, nuclear hormone receptor, beta-catenin, and sonic hedgehog pathways through various 
targets (213-216). For example, MED12 binds to β-catenin through its C-terminal β-catenin 
binding domain. β-catenin is a nuclear effector of the canonical Wnt pathway. MED12 and β-
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catenin, together affect the transcription of targets in the WNT canonical signaling (214). 
MED12 directly binds to Gli-3, affecting the sonic hedgehog pathways. MED12 also contributes 
to epigenetic silencing of RE1-silencing transcription factors (REST) via G9a histone 
methyltransferase in non-neuronal cells (199). Zebra fish models have shown that Med12 can 
interact with Sox9 and Sox10 to carry out gene specific functions during embryonic 
development, possibly suggesting a role as a co-regulator of certain specific transcription factors 
(217-219). 
Rocha and colleagues examined the role of Med12 in mouse embryonic development by 
engineering loxP sites flanking exons 1-7 of Med12 and developing Med12flox mice (220). Using 
the Med12flox mice, they generated both Med12 hypomorphs and Med12 null models. Both these 
models resulted in embryonic lethality; but had different timelines of embryonic arrest. 
Med12hypo embryos (90% Med12 truncated) had severe defects in neural tube closure, heart 
defects, axis elongation, and somitogenesis, which resulted in lethality at E9.5. Whereas, the 
Med12δ1-7 embryos were arrested earlier by E7.5 due to aberration of the Wnt/ β-catenin and 
Wnt/ planar cell polarity (PCP) signaling pathways. This implied a role of Med12 in activating 
canonical Wnt/β-catenin signaling and its gene specific transcription during development. 
Similar effects were observed upon mosaic expression of Med12 during development, with 
embryonic lethality occurring at E9.5 to E12.5 (221). The Med12flox mice have been used in this 
thesis for the purpose of generating Med12 conditional knockouts (220).   
Interestingly, with evolution of species (mammals), the kinase module subunits; MED12, 
MED13 and CDK8 have undergone gene duplication to give rise to paralogs as MED12L, 
MED13L and CDK19 respectively with high sequence similarity (222, 223). MED12L, MED13L 
and CDK19 are part of the mammalian mediator complex, but their functions remain elusive. 
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The addition of these paralogs to the complex may indicate towards the extended functions of the 
mediator complex, including gene-specific or tissue-specific regulation (176).  
1.3.6 Animal models of leiomyomas 
Currently, no good animal model for uterine leiomyomas exists, posing a challenge in 
understanding of leiomyomagenesis as well as in development and testing of new drugs. In this 
section we will discuss three such animal models, which were generated with some relevance to 
leiomyoma biology and in an attempt to develop a model with a phenotype similar to that of 
human leiomyomas. Unfortunately, most of the phenotypes displayed by these rodent models 
were confined to myometrial hyperplasia and small lesions with ECM deposits.  
The Eker rat, carrying a heterozygous germline mutation in Tsc2Ek/+ was the first model 
characterized, where leiomyomas were coincidentally observed in 65% of   Tsc2Ek/+ female 
carrier rats by 18 months of age (147). The model was developed initially to study the tuberous 
sclerosis complex and in addition to leiomyomas, this model develops renal cell carcinomas and 
hemangiosarcomas. The leiomyomas in this model often have aberrant expression of HMGA2 
and were also responsive to steroid hormones (148). ELT Cell lines were also developed from 
leiomyomas of the Eker rat model to facilitate an in-vitro model for leiomyomas. Unfortunately, 
the rare occurrence of the tuberous sclerosis syndrome in humans and the long tumor latency 
period in the rodent model neither made this model clinically applicable nor feasible for studying 
uterine leiomyomas.  
Similar to the Eker rat model, a mouse model conditionally expressing Tsc2 mutation in 
the uterine mesenchyme was generated. In this model, Tsc2 conditional knock-out (cKO) led to 
constitutive activation of mTORC1/S6 pathway in uteri causing myometrial hyperplasia and 
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disorganized cells. These lesions were also responsive to steroid hormones, especially to 
estrogen as assessed by ovariectomy followed by estrogen supplementation (224).  
 The next model for leiomyomas was generated by constitutive activation of β-catenin in 
uterine myometrial cells using Amhr2-cre recombinase (225). Females expressing a stable form 
of β-catenin (constitutively activated) in the uterus developed smooth muscle tumors, 
characterized by hyperplasia and ECM deposition and low mitotic index. The severity of the 
phenotype was also affected by age and parity. As Amhr2-cre is also expressed in the stromal 
compartment of the uterus (226), constitutive activation of β-catenin in the uterine stroma also 
lead to the development of endometrial stromal sarcoma-like lesions. Though the model shows 
the effect of sustained activation of WNT signaling on mesenchymal tumors, the development of 
stromal tumors and indirect mechanistic relevance to human data increase the challenges of 
using this model to successfully study leiomyomas. 
 Yet another approach of generating a transgenic mouse model was by overexpressing 
hGPR10-driven with calbindin-D9K promoter (227). This approach stemmed from the fact that 
human leiomyomas had higher expression of GPR10 (neuronal specific G protein coupled 
receptor) due to aberrant loss of REST in the uterus, potentially affecting the PI3K-AKT-mTOR 
signaling. Yet again, the GPR10 model showed hyperplasia and ECM deposits, but no significant 
large lesions were observed. Thus a lack of good models to understand leiomyomagenesis 
encouraged us to develop such a model, which would not only provide us a tool to study 
leiomyomas but would also provide a platform to test targeted therapeutics against leiomyomas. 
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1.3.7 Public health significance 
Uterine leiomyoma or fibroids are some of the most common clinically relevant solid tumors 
occurring in women of reproductive age. More than five million women in the U.S suffer from 
fibroids. The prevalence of this condition may be as high as 70% taking into account the 
occurrence of asymptomatic leiomyomas (2). About 25% of leiomyomas are clinically diagnosed 
and can cause severe morbidity in women including heavy menstrual bleeding and associated 
anemia, pelvic pain, infertility (4-7, 15). Due to the recurring nature of these tumors, a partial 
myomectomy or hormonal antagonists only help with temporary management. Currently, a 
hysterectomy is the only permanent solution to recurrent fibroids (15, 228).  
About 300,000 hysterectomies per year are associated with fibroids in the United States 
(8, 229). This also results in humongous health care costs with approximately $4.1-9.4 billion 
spent every year (surgery, hospital admissions, outpatient visits, and medications) on the 
treatment of leiomyomas (230). However, the lack of an understanding of the etiology or the lack 
of a clinically relevant model makes it difficult to develop new treatment alternatives to 
hysterectomies. Our current approach on developing animal models for fibroids will be an 
essential step in understanding the role of MED12 in uterine leiomyomas, which together with 
the models will be an invaluable tool for developing new treatment strategies against 
leiomyomas as an alternative to hysterectomy. 
1.3.8  Summary 
Ever since uterine leiomyomas have been studied, there have been more speculations than 
evidence regarding the etiology of these tumors. The most promising cytogenetic etiological 
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evidence in the past two decades has implicated chromosome 12q14-15 translocations, 7q 
deletions and 6p21 rearrangements in the etiology of a subset of leiomyomas (78). The advent of 
next generation sequencing technologies, including whole genome and whole exome sequencing 
has revolutionized the era of cancer genomics and we, like many others sought these 
technologies to discover novel variants associated with leiomyoma formation. The discovery of 
MED12 exon 2 variants in 70% of leiomyomas transformed the field, by providing a novel 
candidate driver gene to pursue. We set out to functionally validate this variant by generating 
animal models for Med12 variants. Thus, my thesis work focuses on tackling the following 
questions: 
a) Can Med12 exon 2 variants cause leiomyomas? 
b) Do Med12 exon 2 variants cause leiomyomas via loss of function or gain of function 
mechanisms? 
c) Is Med12 important for maintaining fertility and the normal functionality of the 
uterus? 
d)  Can Med12 exon 2 variants cause the underlying cytogenetic abnormalities 
associated with uterine leiomyomas? 
As means to address the above questions, we have generated and characterized conditional loss 
of function and gain of function mouse models of Med12 exon 2 variants. This dissertation work 
will discuss the various phenotypes observed in both of these models, revealing the role of 





2.0  LOSS OF MED12 CAUSES INFERTILITY BUT DOES NOT STIMULATE 
TUMORIGENESIS   
Part of the work in Chapter 2 have been published in the Journal of Clinical Investigation.  
2.1 INTRODUCTION 
Uterine leiomyomas are the most common gynecological tumors occurring in women of 
reproductive years, yet the genetic factors associated with the causation and progression of these 
tumors are not well understood. Using whole exome sequencing approaches, others and we have 
shown that MED12 exon 2 mutations are strongly associated with leiomyomas (159, 161). As 
Med12 is present on the X chromosome, there has been speculation regarding the mechanism of 
these mutations causing tumors via loss of function or a gain of function mechanism. Presently, 
no good in vitro models exist as MED12 mutated cells do not survive in culture (231). Neither an 
in vivo model nor an in-vitro with Med12 mutations replicating the human condition is presently 
available. Med12 has already been shown to be important during development as Med12 null 
embryos are arrested at E7.5 due to impaired mesoderm formation and defective Wnt/β-catenin 
signaling pathway (220). Although Med12 is part of the CDK8 sub-complex, it can carry out 
functions independent of CDK8 kinase activity (212). Currently, we understand that the gene is 
important for development, but what role Med12 plays in uterine development, function or in the 
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development of uterine leiomyomas remains unknown. To understand the roles of Med12, we 
decided to generate mouse models of Med12, as it would allow us to study genotype phenotype 
effects without confounding variables (environment). Also, developing in vivo models are 
advantageous in tumor studies as they provide a “niche” a microenvironment essential for the 
progression of the tumor. The embryonic lethality of Med12 global knockouts required us to use 
conditional knockout mice (220).  Med12 is highly conserved among all eukaryotes, allowing us 
to develop mouse models as a means to study the function of Med12 in a tissue specific manner. 
We utilized the Med12 floxed (flanked by loxP) (Med12fl/fl) animals (220) along-with anti 
Mullerian receptor type II cre (Amhr2-cre) (226) animals to generate a loss of function model of 
Med12, by deleting Med12 exon 1-7 in the uterine mesenchyme. The aim of this study was to 
systematically analyze the phenotypic effects of loss of Med12 in the uterine mesenchyme with 
regards to either tumorigenic changes or any other functional effects on the female reproductive 
tract. 
2.2 MATERIALS AND METHODS 
Animal care and experimentation 
Experiments involving mice were approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee and in accordance with the NIH guidelines for humane care of animals. 
Dr. Heinrich Schrewe generously donated the Med12flox mice (220). The Amhr2-cre mice were a 
kind gift of Dr. Richard Behringer (226). The mT/mG mice (GT(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Lou) 
and the Zp3-cre (Tg(Zp3-cre)93Knw/J) mice were obtained from the Jackson Laboratory (Stock 
#007576, # 003651). The Gdf9-cre Tg(Gdf9-icre)5092Coo/J mice were a kind gift of Dr. Austin 
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Cooney (232). The DNA from tail biopsies was used to confirm the genotypes, using standard 
PCR protocols. The primer sets and the PCR protocol used to distinguish Med12 wild-type and 
the recombined alleles in tissue genomic DNA have previously been described (220). Jackson 
laboratory PCR protocols were followed for Amhr2-cre, Gdf9-cre, and Zp3-cre mice. The 
Med12flox, Amhr2-cre, Zp3-cre, Gdf9-cre lines were maintained on a C57BL/6/129Sv hybrid 
background. Litters were weaned at 3 weeks, and breeding pairs were set up at 6 weeks of age. 
All animals were housed under a 12-hour light, 12-hour dark schedule and provided food and 
water ad libitum. 
Histological analyses 
Gross morphology and histology assessments were performed on greater than six weeks of age 
adult females. Prior to harvesting uteri, all females were estrous synchronized with 
intraperitoneal injections of 5 IU PMSG followed by 5 IU of hCG after 48 hours. Females were 
euthanized 20 hours after hCG administration, and uteri were fixed in 10% formalin, processed, 
embedded in paraffin, serially sectioned (6 µm), and stained with hematoxylin and eosin. For 
frozen sections, tissues were embedded in optimal cutting temperature compound and were snap-
frozen in liquid nitrogen. Sections were obtained using a Leica cryostat (6 µm). At least four 
pairs of uteri of each genotype were subjected to gross and microscopic analysis for each 
time point. Images were acquired using an Axio Scope.A1 microscope (Zeiss) equipped with a 
digital camera (Zeiss) and an AxioVision (v4.8) imaging software.  
Histomorphometric analysis 
For histomorphometric analyses, every fifth section was obtained from the long axis of the ovary 
(n=3), stained with periodic-acid and schiff  base, photographed and oocytes containing nuclei 
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were scored. The mean of the total score of oocytes for all the sections was considered as the 
oocyte count per ovary. Primordial follicles were defined as small oocytes (<20µm) surrounded 
by flat epithelial cells. Primary follicles were defined as having larger oocytes surrounded by 
a single layer of cuboidal granulosa cells; secondary follicles defined by two or more layers 
of granulosa cells and pre-antral follicles by the presence of antral fluid (233). 
Med12 antibody generation 
Med12 antigen was produced by cloning the C-terminus of mouse Med12 (561 bp) in the pET-
23b vector (His tag) and expressing the Med12 protein under optimized conditions. The 
expressed protein was purified using nickel resin columns (Novagen). The purified antigen was 
used to immunize guinea pigs. Immunization of guinea pigs was carried out at Cocalico 
Biologicals  (Reamstown, PA). Exsanguination serum containing Med12 antibodies was used for 
further downstream applications. 
Immunofluorescence 
Immunofluorescence was performed on 6-µm frozen sections and subjected to antigen retrieval 
using 10 mM sodium citrate (PH 6.0) for 20 min. Sections were blocked with 3% bovine serum 
albumin for 45 min, followed by incubation with anti- smooth muscle actin (A5228, Sigma 
Aldrich) and anti-Med12 antibodies (custom designed) at 4°C overnight. Following primary 
antibody incubation, sections were washed and incubated in secondary Alexa Fluor 488 (Life 
Technologies) and Alexa Fluor 647 (Life Technologies) and co-stained with DAPI. The sections 
were mounted with Vectashield mounting medium containing DAPI. Images were taken with a 
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Nikon A1 confocal microscope equipped with a digital camera and NIS-Elements software 
(Nikon). For quantitation of Med12 expression, about 300 uterine mesenchyme cells were 
counted for Med12 positive cells in three independent uteri (two cross-sections each).  
To assess the fluorescent signals in the mT/mG reporter mice, frozen sections were washed three 
times in PBS and stained with DAPI. mT (Tomato) and mG (Green) signals were analyzed and 
scored in 300 uterine myometrial cells.  
Reverse transcription and quantitative real-time PCR 
Total RNA was isolated from frozen uteri using the RNeasy Mini Kit (Qiagen). One microgram 
of total RNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen). 
Med12 gene expression was analyzed by real-time quantitative polymerase chain reaction. A 
SYBR Green detection system (Bio-Rad CFX96 PCR Detect System) was used, along with 
customized Med12 primer sets: Med126-7F: CTGACTTGGGTGCTTGAGTGTT and Med12 6-
7R: CCAATCTCCGGGTACAGAAGTA. Melt curve analysis was performed when using 
SYBR Green to verify a single amplification peak. Data were normalized to an endogenous 
reference (GAPDH) and then relative mRNA expression was calculated using the 2-ΔΔCT method. 
Superovulation 
Superovulation was carried out on 3-5 week old mutant and control female mice with IP 
injections of 5 IU PMSG (Sigma-Aldrich) followed by 5IU hCG after 46-48 hours. Twenty 
hours following hCG administration, females were euthanized, and their oviducts were removed. 
The cumulus-oocyte complexes were separated from the ampulla region of each oviduct by 
puncturing the oviduct. Cumulus cells were then released by incubating the complex in 0.5mg/ml 
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hyaluronidase (Sigma-Aldrich) in DMEM media (Invitrogen). Isolated oocytes were assessed for 
morphology and scored.  
Fertility and Copulation Studies 
The fertility status of mice was examined by housing female mice with a proven male stud and 
vice-versa for at least a period of six months. Data such as litter size, litters per month and the 
pup sexes were recorded over successive pregnancies for a period of at-least 6 months. 
Copulation studies were conducted on estrous synchronized females (administering 5IU PMSG 
followed by hCG) with proven stud males overnight. Following morning the males and females 
were separated and the females were examined for the presence of seminal plugs. The presence 
of the seminal plugs was considered as 0.5dpc. 
Statistical analysis 
Two-tailed Student’s t-test was applied to determine the difference of means between two groups 
and one-way ANOVA test was used to determine the differences among multiple groups using 
GraphPad Prism 4.0 software. Significance was defined at p<0.05. 
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2.3 RESULTS 
2.3.1 Generation of conditional loss of function model of Med12 
We first determined whether the conditional inactivation of Med12 causes leiomyomas. Since 
Med12 is expressed from the X chromosome, random X-chromosome inactivation will lead to 
random expression of either the paternal or maternal Med12 locus in uterine myometrial cells. 
We chose Amhr2- driven cre recombinase (226) to delete Med12 from the uterine mesenchyme 
and granulosa cells of the ovary at E13.5. Since Amhr2-cre acts well after X-chromosome 
inactivation is established (E6.5) (234), loss of Med12 function will not lead to skewed X-
inactivation in mouse uteri. One of the key parameters of our experimentation was the efficiency 
of the cre allele used to delete the floxed allele. To assess the cre-recombination in our hands, we 
crossed the Amhr2-cre mice with the double-fluorescent cre- reporter mT/mG mice (235), which 
express red fluorescence in all tissues and green fluorescence upon cre- mediated recombination. 
Based on our results, (Figure 2.1A, B), about 60% of uterine mesenchymal cells underwent Cre-
mediated excision. As 60% Cre efficiency was sufficient for our experiments, we went ahead and 
utilized the Amhr2-cre mice to generate Med12 cKO animals. 
We crossed Amhr2-cre with Med12fl/fl animals to generate Med12fl/+Amhr2-cre (het cKO) 
females and crossed Med12fl/yAmhr2-cre with Med12fl/fl animals to generate Med12fl/fl Amhr2-cre 
animals (Med12 cKO) (Figure 2.1C). We used different breeding schemes to generate het Med12 
cKO and Med12 cKO animals to introduce the cre alleles from the males and avoid nonspecific 
maternal cre effects (236). In the Med12fl/+Amhr2-cre females we studied the effects of Med12 in 
a subpopulation of cells, where the expression of the Med12 floxed allele or the wild-type allele 
was dependent on random X chromosome inactivation. In the Med12fl/flAmhr2-cre females we 
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could circumvent this problem, as both alleles were floxed. In our models, Amhr2-cre acts to 
delete the floxed sites flanking Med12 exons 1-7, resulting in ablation of Med12 in the uterine 
mesenchyme and the granulosa cells of the ovary at E13.5.  
Recombination of the Med12flox allele was shown in the uteri of both Med12fl/+Amhr2-cre 
and Med12fl/fl Amhr2-cre females (Figure 2.1D). The Amhr2-cre-mediated floxed allele 
recombination was also specific to the uterus and did not occur in other organs (Figure 2.1E). 
Quantitative real time PCR analysis showed that Med12 mRNA levels were decreased in 
Med12fl/+Amhr2-cre uteri (Figure 2.1F).  We had also generated custom Med12 antibodies to 
determine Med12 localization and expression in the uterus. Utilizing the Med12 antibody we 
performed immunofluorescence and co-stained with α-SMA (cytoplasmic) and DAPI (nuclear) 
(Figure 2.1G). Interestingly, Med12 seemed to be mostly expressed in the myometrial layer of 
the uterus with cytoplasmic expression as observed by the Sma and Med12 merge (orange) and 
nuclear pattern of expression as observed by Med12 and DAPI merge (light blue). The nuclear-
cytoplasmic shuttling pattern has also been observed in a variety of cancer cell lines including 
lung and colon cancer cell lines (237). Quantification of cells expressing Med12 in Med12fl/fl, 
Med12fl/+Amhr2-cre and Med12fl/flAmhr2-cre uteri showed a 20-25% decrease of Med12 in 
Med12fl/+Amhr2-cre uteri and 40% decrease in Med12fl/flAmhr2-cre uteri, both with statistical 
significance (Figure 2.1H).  
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Figure 2.1. Evaluation of Amhr2-cre activity, Med12 recombination and expression in loss of Med12 uteri 
We used mT/mG mice to assess the efficiency of Amhr2-cre recombination. (A) 16-week-old mT/mG mice 
displaying ubiquitous mT (Tomato) expression prior to recombination. (B) 16-week-old mT/mG Amhr2-cre uteri 
display mG (Green) expression in cells having undergone cre-mediated excision. The non-recombined cells still 
display mT expression. (C) Schematic representation of the breeding strategy used to generate Med12 het cKO 
(Med12fl/+ Amhr2-cre) and Med12 cKO (Med12fl/fl Amhr2-cre) females (D) Recombination of Med12 floxed alleles 
in uterine genomic DNA of Med12fl/+ Amhr2-cre (Lane 2) and Med12fl/fl Amhr2-cre (Lane 3) females. Med12 
recombined bands are detected at 330 bp in the genomic DNA of cKO (Lane 2 & 3) but not in the uterine genomic 
DNA of controls (Med12fl/fl). (E) The recombined bands (330 bp) were only detected in the genomic DNA of the 
uterus and not in other tissues such as the liver, heart, or kidneys. (F) Relative Med12 mRNA levels are down-
regulated (5-fold) in uteri of het cKO (n=4) as compared to Med12fl/fl uteri (n=4) (p<0.05). (G) Sections from 
Med12fl/fl, Med12fl/+Amhr2-cre and Med12fl/flAmhr2-cre uteri were co-stained with Med12 antibody, SMA and DAPI 
and analyzed for Med12 expression pattern using immunofluorescence. The white arrows in (G) indicate regions 
with loss Med12 in the uterine myometrial cells (H) About 20% of Med12fl/+Amhr2-cre cells and about 45% of 
Med12fl/flAmhr2-cre uterine cells lack Med12 compared to controls, with statistical significance (p<0.05) (n=3). 
Student’s t test was applied to (F) and ANOVA was carried out t compare the groups in (H). Data is presented as 
mean ± SEM. Scale bars = 50μm (A, B, G). 
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2.3.2 Med12 cKO females have atrophic uteri 
We first evaluated the uteri of Med12fl/+ Amhr2-cre females starting at 6 weeks of age and 
continued to evaluate at 12, 16, 24 and 32-week time points (n=4 at each time point). The 
morphology and histology of Med12fl/+ Amhr2-cre (Figure 2.2 D, G) uteri appeared normal at all 
time points. We did not observe any leiomyoma formation or hyperplasia either in the 
nulliparous or multiparous Med12fl/+ Amhr2-cre females (Figure 2.2B, D, G). These results 
indicated that loss of Med12 was not the likely mechanism of leiomyoma formation.  As random 
X chromosome inactivation may play a role in influencing the results observed in the 
Med12fl/+ Amhr2-cre animals, we decided to generate animals where both Med12 alleles are 
floxed. Similar to the het cKO females, we evaluated the uterine morphology and histology of   
Med12fl/fl Amhr2-cre (Med12 cKO) females at 6,12,16,24 and 32-week age time points. We did 
not observe any pathological changes associated with leiomyoma formation but on the contrary 
we observed hypoplastic reproductive tracts of Med12 cKO females (Figure 2.2A) and 
correspondingly the uterine weights of the Med12 cKO were 50% lesser than that of controls 
(p<0.01) (Figure 2.2B). Histological evaluation also corroborated these findings as the uterine 
myometrial layer was severely diminished (Figure 2.2E, H). In addition, there was a noticeable 
reduction in the number of glandular epithelium (Figure 2.2H). It is possible that the loss of 
Med12 can affect glandular development as the reporter cre experiments show cre recombination 
occurring in glandular epithelium as well (Figure 2.1A). 
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Figure 2.2. Med12fl/fl Amhr2-cre females have hypoplastic reproductive tract 
(A) Gross morphology of 12-week old reproductive tracts, showing healthy control (Med12fl/fl) uteri as
compared to reproductive tracts of Med12 cKO females (Med12fl/fl Amhr2-cre). Uterine weights of control
(n=7), het cKO (n=7) and Med12 cKO (n=7) corroborate these findings with a 50% drop in uterine weights
of Med12 cKO females as compared to controls (p<0.01) (t-test), whereas the uterine weights of Med12fl/+ 
Amhr2-cre mice (n=7) did not significantly differ from that of Med12fl/+. Histological evaluation was
conducted on uteri from 8, 12, 16, 24, 32-week control, het cKO and Med12 cKO females. At 12-weeks
control uteri (C) (Med12fl/fl) were normal. (D) Uteri of het cKO (Med12fl/+ Amhr2-cre) also lacked any gross
abnormalities or leiomyoma-like lesions. (E) Corroborating the gross morphology, the uteri of Med12 cKO,
displayed a hypoplastic uterus, with diminished myometrial thickness and a decrease in the number of
glandular epithelia. The white dotted regions in (C), (D) and (E) are shown at higher magnification in panels
(F), (G) and (H), respectively. Data are presented as means ± SEM. ES-endometrial stroma; MY-
myometrium; EM-endometrium. Scale bars = 2000μm(A) 0.5μm (C,D,E), 100μm (F,G,H).
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2.3.3 Med12 cKO females are infertile 
We next investigated the reproductive and the fertility outcomes of Med12 cKO and het cKO 
females by breeding them with proven male studs for a period of six months. Interestingly, the 
Med12 cKO females were infertile and het cKO females were sub-fertile (p<0.001) (Figure 
3.3A). If the Med12 floxed allele is expressed and excised, then the cell is likely to behave like a 
Med12 cKO, whereas if the cell expresses the wild-type Med12 allele then we would expect the 
cell to behave like wild type. Thus the random pattern of X inactivation in het cKO uteri would 
explain the mosaicism observed in the fertility outcomes of het cKO females (Figure 2.3A). 
Another interesting aspect of our findings is the slight sub-fertility of the Med12 cKO (Med12fl/y 
Amhr2-cre) males (p<0.05) (Figure 2.3B).  Previous reports have shown that in addition to the 
female reproductive tracts, Amhr2-cre is also expressed in Leydig cells (somatic) of the testis 
(238) and the loss of Med12 in these cells could affect male fertility. We also observed an
unexpected discrepancy in the number of males to females with a tendency of higher number of 
males born in each litter. The sex ratio was determined to be about 3:2 (p<0.05) (Figure 2.3C). 
The possibility of sex reversal as a cause of sex ratio discrepancies was ruled out by confirming 
the presence of SRY (sex-determining region Y) gene in several sets of male pups born from the 
Med12fl/y Amhr2-cre and Med12fl/fl mating. 
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Figure 2.3. Evaluation of breeding in Med12 cKO males and females 
(A) Fertility data collected from Med12fl/fl, Med12fl/+ Amhr2-cre and Med12fl/fl Amhr2-cre females by breeding them
with wild-type stud males for a period of six months. The Med12fl/+ Amhr2-cre females are sub-fertile and
Med12fl/fl Amhr2-cre females are infertile (p<0.001). (B) Male fertility data collected from Med12fl/y Amhr2-cre
males also show slight sub-fertility as compared to controls (Med12fl/y) when mated with Med12fl/fl females. (C)
Representative dot plot graph showing the skewed sex ratios in pups born from Med12fl/y Amhr2-cre x Med12fl/fl
mating. The observed male to female sex ratio is 3:2 (p<0.05) (n=10). Data are represented as mean± SEM.
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2.3.4 Ovulation occurs under external gonadotropic stimulus in Med12 cKO females 
Amhr2-cre is expressed in the uterine mesenchyme, oviduct and granulosa cells of the ovary 
(226). Hence, deletion of Med12 in the above regions of the female reproductive tract may either 
contribute individually or collectively to the infertility phenotype observed in Med12 cKO 
females. To define the cause of fertility, we examined the ovarian morphology and histology of 
adult females. Upon histological evaluation, control ovaries (n=5) (Med12fl/fl) at 12-weeks of age 
appeared normal and contained follicles at various stages of follicular development (Figure 2.4 
A, D). Similar to the controls, het cKO ovaries also had normal stages of follicular development 
but had the presence of unique “follicular nest” like structures, described as hyper chromatically 
stained, solid, disorganized cells associated with dying follicles (Figure 2.4 B, E)(239). 
Interestingly, the Med12 cKO ovaries appeared to be of normal size, but there were a number of 
“follicular nests” accompanied by dying follicles suggesting a block in follicular development.   
We next tested the ovulatory response of het cKO   and Med12 cKO ovaries, using   external 
gonadotropic   stimulus.   Superovulation was performed on three-four week age het cKO, 
Med12 cKO and control mice.    No significant differences were seen in the oocyte numbers 
recovered from the ampulla region of the oviduct between the mice of various genotypes (Figure 
2.4G). Correspondingly, the histology of superovulated Med12 cKO ovaries appeared normal 
with follicles of all developmental stages and corpora lutea (CL) present in the ovaries (Figure 
2.4H). These results suggest that despite normal ovulatory response under external gonadotropic 
stimulus, reproductive function is affected. To determine the number of follicles in the Med12 
cKO ovaries, we quantitated non-atretic follicles at secondary, pre-antral, large antral, 
preovulatory, corpora lutea and total atretic follicles in 6-week control (Med12fl/fl) (n=3) and 
Med12 cKO (n=3) ovaries. Upon quantitation, it became evident that the numbers of antral, 
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preovulatory and large antral follicles in the Med12 cKO ovaries were few. There were also a 
remarkably large number of atretic follicles in these ovaries (Figure 2.4I). These results suggest a 
block in follicular development at the secondary follicular stage in the absence of external 
gonadotropic stimulus.  
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Figure 2.4. Assessment of ovarian histology and ovulation assay  
(A) Ovarian histology of 12 week control, Med12fl/fl females (n=5) (B) Med12fl/+ Amhr2-cre females n=5) (C)
Med12fl/fl Amhr2-cre females. Higher magnification of (A-C) is shown in (D-F), respectively. (F) Black arrows
indicate the presence of hyper chromatically stained granulosa cells and accompanying dying follicles indicated by
the collapsing zona pellucida layers in Med12 cKO ovaries. (G) Upon performing superovulation assays the number
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of ovulated eggs did not significantly differ between control (Med12fl/fl) (n=5), Med12 het cKO (n=5) and Med12 
cKO (n=5) females. (H) Histology of 4 week PMSG- hCG treated ovaries. (I) Quantification of secondary, pre-
antral (PA), large-antral (LA), corpus luteum (CL) and atretic follicles in 6-week Med12 cKO ovaries (n=3 pairs). 
Data are presented as mean ± SEM. Scale bars = 0.5μm (A,B,C), 100μm (D,E,F,H). 
2.3.5 Med12 is a maternal effect gene important for somatic cell but not germ cell 
development 
In section 2.3.1, we had shown the Amhr2-cre recombinase activity was about 60%. To increase 
the efficiency of floxed allele deletion in the myometrium and decrease the incidence of 
mosaicism, we utilized oocyte specific growth differentiation factor driven cre (Gdf9-cre) (232) 
and zona pellucida driven-cre (Zp3-cre) (240) to generate Med12fl/- females. The generation of 
Med12fl/- animals is advantageous as the Cre recombinase would have to eliminate floxed allele 
from only 50% of cells. 
We tried generating Med12fl/+ Gdf9-cre mice by mating Med12fl/fl females with Gdf9-cre 
males (Figure 2.5A). Unfortunately we were unable to generate Med12fl/+ Gdf9-cre males or 
females. Typically Gdf9-cre is expressed in oocytes, as early as primordial follicles of PD3 
ovaries (232) but reports have also suggested paternal leaky expression of Gdf9-cre (241). This 
would explain the possible embryonic lethality of   Med12fl/+ Gdf9-cre pups.  
As leaky expression of Gdf9-cre did not work in favor of generating Med12fl/- mice, we 
decided to use Zp3-cre as an alternative. Zp3-cre is expressed at PD10 in the primary follicles of 
the ovary(240). We generated Med12fl/+ Zp3-cre females (Figure 2.5B), where about 50% of the 
follicles would lack Med12 and the rest 50% would have wild-type Med12. Using the Med12fl/+ 
Zp3-cre females we again failed to generate Med12fl/- females, suggesting embryonic lethality of 
pups lacking maternal Med12. We tried an alternative strategy to generate Med12fl/fl Zp3-cre by 
utilizing Med12fl/y Zp3-cre males and mating them with Med12fl/fl females. Using this strategy 
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we were able to generate Med12fl/fl Zp3-cre females (primary oocytes will lack Med12). 
Interestingly, the Med12fl/fl Zp3-cre (n=2) when mated with wild-type proven male studs did not 
give rise to any pups either. We evaluated the ovarian histology of Med12fl/fl Zp3-cre females to 
see if normal oogenesis could occur in the absence of Med12 from the oocytes. Remarkably, 
adult Med12fl/fl Zp3-cre ovaries looked normal with follicles of all developmental stages present 
(Figure 2.5 C, D). The likely explanation for the Med12fl/fl Zp3-cre female infertility is the 
embryonic lethality of pups lacking maternal Med12. These results are consistent with the 
interpretation that Med12 is a maternal effect gene. 
55 
Figure 2.5.  Breeding schemes to generate Med12fl/- females and evaluation of Med12fl/fl Zp3-cre ovaries 
(A) Breeding scheme used to generate Med12fl/+ Gdf9-cre mice. (B) Illustration of breeding schemes used to
generate Med12fl/fl Zp3-cre mice. We were unable to generate Med12fl/- females using the above two strategies.
(C) Histology of 12-week control, Med12fl/fl ovaries and (D) 12 week Med12fl/fl Zp3-cre ovaries exhibiting
normal oogenesis and ovarian histology. Scale bars= 0.5 μm (C, D).
2.3.6 Med12 cKO uteri infrequently develop tumors other than leiomyomas  
Generally the histology of Med12 cKO uteri revealed hypoplastic uteri but in three of thirty 
Med12 cKO uteri, we observed solid tumors other than leiomyomas. In a 16 week Med12 cKO 
uterus we observed a solid mass and appeared to be either a leiomyosarcoma or solid tumor of 
unknown malignant potential (STUMP) (Figure 2.6A, B). Another 16 week Med12 cKO uteri 
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presented with changes associated with adenocarcinoma (stroma) and necrosis (Figure 2.6C, D). 
The third solid tumor was observed in the uteri 24-week old Med12 cKO female. Upon 
histological examination it was apparent that the tumor was a teratoma as different organ cell 
types were present within the same tumor (Figure 2.6 E, F). Therefore, we could conclude that 
loss of Med12 does not stimulate leiomyoma formation but occasionally stimulates other types 
of solid tumors. 
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Figure 2.6. Solid tumors in Med12 cKO uteri 
(A) A solid tumor in 16 week Med12 cKO uteri. Higher magnification of the tumor cells from (A) is
shown in (B). (C,D) Histology of 16-week Med12 cKO uteri displaying adenocarcinoma-like phenotype
and associated necrosis. (E) Histology of 24-week Med12 cKO uteri displaying a teratoma. (F) Higher
magnification shows different cell types present in the solid tumor, typical of teratoma histology. Scale
bars =1000 μm (E), 0.5μm (A,C), 100μm (B,D,F).
58 
2.4 DISCUSSION 
Med12 exon 2 mutations occur in about 70% of human leiomyomas, yet the mechanisms of these 
mutations in tumor formation are not understood (159, 161). Med12 is known to act as a 
transcriptional regulator of RNA pol II complex but its role in the uterus or reproductive function 
is unknown (204). Therefore, understanding the mechanism of Med12 in tumor causation and 
reproductive function is important. To address these questions, we generated het cKO and 
Med12 cKO females using the Med12fl/fl (220) and Amhr2-cre (226) mice.  
 The uterine histology of het cKO appeared normal, with the absence of any tumorous 
lesions. Contrary to the phenotype of het cKO females, the uterine phenotype of Med12 cKO 
females was more dramatic with diminished myometrial layers causing hypoplastic uteri. Our 
results show that the depletion of Med12 not only caused uterine histological abnormalities in 
Med12 cKO females, but also rendered them infertile. Interestingly, the het cKO females were 
sub-fertile with large variability in the phenotype. This variability in the phenotype can be 
ascribed to the mosaicism caused due to random X inactivation in the female reproductive tract. 
In addition, deletion of Med12 from the interstitial and Leydig cells of the testis (Med12fl/y 
Amhr2-cre) causes mild subfertility in males. The sex ratios of pups generated from the Med12fl/y 
Amhr2-cre males are also slightly skewed. The reasons for the skewed sex ratios are not clear.  
As Amhr2-cre is also expressed in the ovarian granulosa cells (226), we considered the 
possibility that loss of Med12 in the ovarian granulosa cells could contribute to impaired 
ovulation in Med12 cKO females contributing to the infertility phenotype. Though the size of 
Med12 cKO ovaries appeared to be normal (histology and morphology), there was an apparent 
lack of pre-antral, pre-ovulatory follicles and corpora lutea. Instead, a large number of atretic 
follicles were present in the Med12 cKO ovaries. These results indicated a block in ovulation at 
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the antral follicle stage in Med12 cKO ovaries. Cumulatively, the phenotype observed in the 
uterus and ovaries of Med12 cKO females was reminiscent of ER knockout females (242-244). 
Therefore, it is possible that Med12 may play a role in steroidogenesis, a role that might explain 
the recurrence of Med12 mutations in female specific steroid driven tumors. 
In an attempt to improve the cre efficiency we tried generating Med12fl/- mice using 
oocyte specific Zp3-cre or Gdf9-cre, but were unsuccessful in generating any Med12fl/- pups. It is 
likely that Med12fl/- status resulted in embryonic lethality as maternal Med12 maybe essential to 
complete fertilization and blastocyst formation. Analysis of Med12fl/fl Zp3-cre ovaries showed 
that Med12 was not essential for oogenesis but rather was essential for development, 
maintenance and functioning of the somatic component supporting oocyte growth (granulosa 
cells). The Med12fl/fl Zp3-cre females did not give birth to any pups either. This is likely due to 
the fact that paternal Med12 expression is not sufficient to pass through embryonic development 
resulting in lethality. Rocha and colleagues have also observed similar results upon using CMV-
cre to delete Med12 floxed sites during embryogenesis (221). 
Although we never saw leiomyoma-like lesions, we observed rare occurrences of three 
different solid tumors (3/30) including similar to a leiomyosarcoma, a teratoma and 
adenocarcinoma in the Med12 cKO females. Both Bertsch et al., and Perot et al, have previously 
shown Med12 expression to be inhibited in malignant tumors such as STUMP or 
leiomyosarcomas whereas it was unaltered in benign leiomyomas (164, 172). However it is yet 
to be determined as to what targets are triggered by the loss of Med12 leading to the rare 
occurrence of tumorigenesis in Med12 cKO females. 
In summary, loss of Med12 does not stimulate uterine leiomyomas but causes infertility, 
the mechanism of which is to be determined in the future. 
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3.0  MED12 GAIN OF FUNCTION MUTATION CAUSES LEIOMYOMAS AND 
GENOMIC INSTABILITY  
The majority of the work in Chapter 3 has been published in the Journal of Clinical 
Investigation.  
3.1 INTRODUCTION 
The most common MED12 mutation in leiomyomas among American women is a non-
synonymous variant, c.131G>A, predicted to substitute a highly conserved amino acid glycine 
with aspartic (p.Gly44Asp) (161). We wanted to investigate whether the MED12 mutations 
found in women cause leiomyomas and associated instability, by generating a similarly mutated 
Med12 knock-in mouse model. Typically, in tumors, a missense variant like p53, can act either 
via loss of function; gain of function, or in a dominant negative manner (245). Based on the 
results from Chapter 2, we were able to conclude that Med12 exon 2 variants do not act through 
a loss of function mechanism. We needed to develop a mouse model that would allow us to study 
the mechanism of the Med12 exon 2 variants either in the presence or in the absence of X-
chromosome wild-type Med12.  We designed a strategy such that the most common human 
Med12 exon 2 missense variant (c.131G>A) was engineered into a cDNA and was inserted into 
the autosomal ROSA locus. Using these mice, we generated models where Med12 missense 
variant c.131G>A was expressed either with or without X-chromosome wild-type Med12 and 
have shown that Med12 exon 2 variants cause leiomyomas in a gain of function manner. Further, 
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we have investigated the genomic landscape of these tumors, only to reveal that the Med12 exon 
2 mutations can also cause associated genomic instability, which may ultimately contribute to 
tumor progression.  
3.2 MATERIALS AND METHODS 
Generation of Med12 Rosa knock-in mice 
Med12 mutated ROSA knock-in mice were generated by introducing the most common missense 
mutation encountered in leiomyomas of American women, c.131G>A (p.Gly44Asp) (161), into 
the Med12 cDNA of the mice. Full-length mouse Med12 cDNA (8.6 kb) was cloned into pEntry 
vector (Invitrogen) in a stepwise fashion. Initially, a small fragment of Med12 (1.6 kb) fragment 
was amplified via PCR from mouse newborn ovary cDNA, using the following primer set: 
pEntry-mMed12 F: CACCATGGCGGCTTTCGGGATCTT and pEntry-mMed12 
R1: GCGGCCGCGAATTCTACTCGCTCACTT. The longer fragment of Med12 (6.5 kb) was 
then obtained through digestion of the Med12 EST clone (BC057119, GE Dharmacon) with 
EcoRI and NOTI. Finally, the smaller fragment was ligated with the larger fragment, and the 
full-length Med12 sequence (8.1 kb) was confirmed by Sanger sequencing. Site-directed 
mutagenesis was performed using QuikChange Multi Site-Directed Mutagenesis Kit 
(Stratagene), with Mde12131AF: 
ACGGCTTTGAATGTAAAACAAGATTTCAATAACCAGCCTGCTGTC and 
Mde12131AR:GACAGCAGGCTGGTTATTGAAATCTTGTTTTACATTCAAAGCCGT 
primers used according to manufacturer instructions. pROSA26-DV1 vector was used to target 
the ROSA26 genomic locus (246). Mutated Med12 cDNA was inserted into the pROSA26-DV1 
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vector, using LR Clonase Enzyme Mix (Invitrogen). Electroporation was performed, using G4 
ES cells, at the MWRI transgenic core. Two ES cell clones were selected for blastocyst injection 
after confirming appropriate integration into the ROSA26 locus using Rosa26 5' probe (Rosa 5' 
probe F: GCTCAGAGACTCACGCAGCCCTAGT and Rosa 5' probe R: 
AGAGTAGGGGGAGGGGAAGAGTCCT) and Rosa26 3' probe (Rosa 3' probe 
F:CTCCCAAGTGTTGGGAACTAAAGATA and Rosa 3' probe 
R: GCTACATCCTGATCTAGTCCTGAA) (Figure3.1A, B).  
 
Animal care and experimentation 
All procedures were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee and are in accordance with the NIH Guide for the Care and the Use of Laboratory 
Animals. Med12 ROSA knock-in mice were maintained on a FVB/C57BL/6/129SV background. 
The DNA from tail biopsies was used to confirm the genotypes, using standard PCR protocols. 
The primer sets used for genotyping Med12 ROSA knock in mice include: Rosa A: 
AAAGTCGCTCTGAGTTGTTAT, Rosa B: GCGAAGAGTTTCTCCTCAACC, and Rosa C: 
GGAGCGGGAGAAATGGATATG. The genotyping protocol was as follows: 95οC 5:00, 94οC 
0:30, 60οC 0:30, 72οC 0:30, 72οC 7:00 for 34 cycles. Breeding pairs were set up at 6 weeks of 
age, and litters were weaned at 3 weeks. All animals were housed under a 12-hour light, 12-hour 
dark schedule and provided food and water ad libitum. 
 
Histological Analysis 
Gross morphology and histology assessments were performed on adult female mice. Prior to 
harvesting the uteri, all females were estrous synchronized with IP injections of 5 IU PMSG 
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followed by 5 IU of hCG after 48 hours. Females were euthanized 20 hours after hCG 
administration, and uteri were fixed in 10% formalin, processed, embedded in paraffin, serially 
sectioned (6 µm), and stained with hematoxylin and eosin. For frozen sections, tissues were 
embedded in O.C.T. medium and were, snap-frozen in liquid nitrogen. Sections were obtained 
using a Leica cryostat (6 µm). At least three pairs of uteri of each genotype were subjected to 
gross and microscopic analysis for each time point. Uteri were also subjected to Masson’s 
Trichrome staining (American MasterTech) according to the manufacturer’s protocol. Images 
were acquired using an Axio Scope.A1 microscope (Zeiss) equipped with a digital camera 
(Zeiss) and an AxioVision (v4.8) imaging software. 
 
Immunohistochemistry and immunofluorescence 
Immunohistochemistry was performed on 6-µm paraffin sections and subjected to antigen 
retrieval with 10 mM sodium citrate (pH 6.0) for 20 minutes. In order to quench endogenous 
peroxidase, sections were treated with 3% hydrogen peroxide and then blocked with 3% bovine 
serum albumin for 45 minutes, followed by incubation with anti- SMA antibody (A5228, Sigma 
Aldrich) overnight at 4°C. After primary antibody incubation, sections were washed and 
incubated in biotinylated secondary antibody for 30 minutes, followed by ABC reagent 
(Vectastain for amplification of signal intensity). DAB Peroxidase Substrate Kit (Vector 
laboratory) was then used to develop the immunoreactive signals. Immunofluorescence was 
conducted on 6-µm frozen sections, using a similar protocol, except that the secondary 
antibodies were Alexa Fluor 488 (Life Technologies) and Alexa Fluor 647 (Life Technologies). 
Primary Anti-FLAG (F7425, Sigma Aldrich) antibody was used for immunofluorescence. The 
sections were mounted with Vectashield mounting medium containing DAPI. Images were taken 
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with a Nikon A1 confocal microscope equipped with a digital camera and NIS-Elements 
software (Nikon).  
 
Western blot analysis 
For Western blots, Nuclear and cytoplasmic extracts were prepared from pulverized mouse 
uterine samples as described previously (247). Equal amounts of protein were loaded and 
resolved on 3-8% Tris-acetate gels (Life Technologies). Membranes were then incubated in 
either anti-FLAG (F7425, Sigma Aldrich) or β-tubulin antibodies (T0198, Sigma Aldrich) 
overnight at 4°C. The following day, the membranes were washed and incubated in respective 
secondary antibodies for 1 hour and developed using ECL-Prime (GE, Amersham). 
 
DNA isolation 
Genomic DNA was isolated from frozen tissue samples using DNeasy Blood & Tissue Kit 
(Qiagen) according to the manufacturer’s protocol and was quantitated using both NanoDrop 
spectrophotometer (Thermo Scientific) and Qubit (Life Technologies). 
 
Array CGH 
Agilent SurePrint G3 Mouse Genome CGH 180K microarray kits were used to conduct array 
CGH on mouse uteri. Genomic DNA from uteri of four Med12fl/+ Med12Rmt/+ Amhr2-cre females 
was used as the “experimental” DNA and corresponding littermate control females without 
Amhr2-cre (Med12fl/+ Med12Rmt/+) as the “reference” DNA. The samples were labeled, 
hybridized, and scanned according to the manufacturer’s protocol. Briefly, 750 ng of 
experimental and reference DNA were digested with Alu I and Rsa I (Promega) and labeled with 
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Cy3-dCTP (experimental) or with Cy5- dCTP (reference). The labeled DNA was purified and 
hybridized, and the arrays were washed, and scanned using an Agilent G2565CA Microarray 
Scanner. Raw data were obtained by Agilent Feature Extraction software and imported into the 
Agilent Genomic Workbench 7.0 software for analysis. DNA copy number changes were 
detected by Genomic Workbench software. The ADM-2 statistical algorithm was used with a 
sensitivity of 6.0. The criteria for making aberration calls included positive calls by the software, 
log2 ratios of >0.25 or less than <-0.25, and the presence of three consecutive affected probes. 
 
Human syntenic mapping 
Mouse chromosomal aberrations were mapped onto human chromosomal loci using the UCSC 
genome browser LiftOver tool (http://genome.ucsc.edu). The gene lists for the human intervals 
were determined by the microarray core website developed jointly by the University of Miami 
and Oklahoma University (www.ccs.miami.edu/cgi-bin/ROH/ROH_analysis_tool.cgi). 
 
Reverse transcription and Med12 variant expression detection 
Total RNA was isolated from frozen uteri using the RNeasy Mini Kit (Qiagen). One microgram 
of total RNA was reverse transcribed using Superscript III reverse transcriptase (Invitrogen).  
Med12 exon 2 C.131 G>A variant was evaluated in mutant mouse uteri by performing PCR on 
cDNA, followed by Sanger sequencing with primers using the following forward and reverse 
oligonucleotide that flanked the Med12 exon 2 C.131 G>A variant: Med12 
F: ATGGCGGCTTTCGGGATCTT and Med12 R: AGTTGGAACTGATCTTGGCAGG 
primers, designed within Primer3 (http://bioinfo.ut.ee/primer3-0.4.0). Sequencing results were 
analyzed using Sequencher software (Gene Codes Corporation). 
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Statistical analysis 
Two-tailed Student’s t-test was applied to determine the difference of means among groups using 
GraphPad Prism 4.0 software (GraphPad Software, CA, USA). Significance was defined at 
p<0.05. 
3.3 RESULTS 
3.3.1 Generation of mutant Med12 Rosa knock in mice (c.131G>A) 
We investigated whether the Med12 c.131G>A variant caused leiomyoma formation, by 
generating a floxed Med12 mutant knock-in mouse model (Figure 3.1A, B). We engineered the 
c.131G>A variant into the mouse Med12 cDNA (Med12mt) fused with a FLAG tag, subcloned it
into the pROSA26-DV1 vector, and integrated it into the autosomal ROSA26 genomic locus. The 
presence of the FLAG reporter, allowed us to distinguish the expression of mutant Med12 from 
wild-type Med12 (Figure 3.1D, F). The mice generated were heterozygous for mutant Med12 
cDNA at the ROSA26 locus (Med12Rmt/+). We mated Med12Rmt/+ with Amhr2-cre mice to 
conditionally express mutated Med12 (c.131G>A) as early as E13.5 in the mouse uterine 
mesenchyme (226). Upon Cre mediated recombination, mutated Med12 expression is driven by 
the ROSA promoter at the ROSA locus.  All the breeding strategies used to generate the mice in 
this chapter have been shown in Figure 3.2 (C, D). 
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Figure 3.1. Generation of ROSA26 Med12 mice that conditionally express Med12 c.131G>A variant 
(A) Mouse Med12 cDNA was mutated and inserted into the pROSA26-DV1 vector (pROSA26DV-1 Med12
c.131G>A) and electroporated into G4 ES cells for homologous recombination with ROSA26 genomic locus
to generate ROSA26 Med12 c.131G>A mice. Mutated Med12 transcripts expressed from the ROSA26 locus
are fused with FLAG and GFP. (B) Southern blot on DNA extracted from recombined G4 ES cells shows
targeting of mutated Med12 to the ROSA26 locus. Probes corresponding to the 5' (blue) and 3' (orange)
targeting ends are expected to generate 17-Kb wild-type and 8.4-kb mutant fragments and 37-kb wild-type
and 8.8-kb mutant fragments, respectively, when genomic DNA is digested with Sac I and Kpn I enzymes.
(C) Uteri from mice that carry the mutation in the absence of Amhr2-cre (Med12fl/+ Med12Rmt/+) do not
express mutant mRNA, while in the presence of Amhr2-cre (Med12fl/+ Med12Rmt/+ Amhr2-cre), uteri show
significant expression of mutant c.131G>A variant (green chromatogram peak, black arrows). (D) Western
blot analysis shows expression of mutant Med12 protein fused with FLAG in Med12Rmt/+ Amhr2-cre uteri as
compared to control (Med12Rmt/+) uteri that are devoid of Amhr2-cre. Tubulin is used as a loading control.
(E,F) Immunostaining with FLAG antibody shows FLAG expression as a marker for mutant Med12
expression in uteri of Med12fl/+ Med12Rmt/+ Amhr2-cre females but not in control uteri (Amhr2-cre). Green:
FLAG expression, Red: DAPI staining. Scale bars = 50µm (E,F).
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Figure 3.2 Models and breeding schemes of mice used in Chapter 3 
(A) Mouse model 1 (Med12fl/+ Med12Rmt/+ Amhr2-cre). A subset of cells express Med12 c.131G>A variant from the
autosomal ROSA locus while X-chromosome–derived Med12 will either be conditionally excised at one locus or
silenced by X-chromosome inactivation at the other locus. Transcription from mutant autosome (Amt/+) is shown by
the arrow, and the promoter region is depicted in green. The blue star indicates Med12 c.131G>A variant. The pink
star indicates the floxed Med12 allele on the X-chromosome (Xcko), which in the presence of Amhr2-cre will lose
exons 1-7. In the cells where Med12 floxed allele is subject to X inactivation inactivated, wild-type Med12 will  be
expressed. In cells with an active Med12 floxed allele, only mutant Med12 will be expressed. The red chromosome
indicates the inactivated X. (B) Mouse model 2 (Med12Rmt/+ Amhr2-cre). A subset of cells that express Amhr2-cre
will express Med12 c.131G>A variant from the autosomal ROSA locus in the presence of X-chromosome wild-type
Med12. Transcription from mutant autosome (Amt/+) is shown by the arrow, and the promoter region is depicted in
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green. Med12 c.131G>A variant is depicted by a blue star. The red chromosome indicates the inactivated X. (C) 
Breeding schemes used to generate Med12fl/+ Med12Rmt/+ Amhr2-cre, Med12fl/fl Med12Rmt/+ Amhr2-cre, Med12fl/fl 
Med12Rmt/mt Amhr2-cre. (D) Breeding schemes used to generate Med12Rmt/+Amhr2-cre and Med12Rmt/mt Amhr2-cre 
females. 
3.3.2 Expression of the Med12 c.131G>A variant on the background of conditional Med12 
knockout causes leiomyomas 
We investigated whether uterine leiomyomas will form in mice that express the Med12 
c.131G>A variant on a conditional knockout background (Figure 3.2A). In this model, we
generated Med12fl/+ Med12Rmt/+ Amhr2-cre females, such that a subset of uterine cells will 
express Med12 c.131G>A on an X-chromosome Med12-null background (Figure 3.2A, C). We 
analyzed the Med12fl/+ Med12Rmt/+ Amhr2-cre female reproductive tracts at 8, 12, 16, 24 weeks 
of age (n=5 at each time point). Nulliparous Med12fl/+ Med12Rmt/+ Amhr2-cre females presented 
with pathological changes associated with leiomyoma formation as early as 8 weeks (Figure 3.3 
B). Histological evaluation revealed that, beyond 12 weeks, 70% of the uteri contained lesions 
consistent with leiomyomas (248). These lesions consisted of extracellular matrix (ECM) 
deposits accompanied by infiltration of fibroblasts and macrophages, hyperplasia, and 
disorganized muscle fiber arrangement leading to complete destruction of myometrial 
architecture (Figure 3.3D-N). Med12fl/+ Med12Rmt/+Amhr2-cre mutant uteri expressed mutant 
Med12 as shown by expression of FLAG, which is fused to mutant Med12 in our ROSA 
construct (Figure 3.1F). The uteri of Med12fl/+ Med12Rmt/+Amhr2-cre females consistently 
weighed 40-50% higher (all time points) compared to Med12fl/+ Med12Rmt/+ uteri (p<0.05) 
(Figure 3.O). 
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It has been noticed that estrogen and progesterone promote leiomyomatous growth, and 
30% of leiomyomas in human pregnancies increase in volume as elaborated in section 1.2.1 (45). 
To corroborate these observations, we studied the effects of mouse parturition on leiomyoma 
growth. Eighty percent of multiparous Med12fl/+ Med12Rmt/+ Amhr2-cre females had leiomyoma-
like lesions. Multiparous Med12fl/+ Med12Rmt/+ Amhr2-cre females often had either grossly 
visible large leiomyomas (Figure 3.4 A) or multiple small leiomyoma-like nodules (Figure 
3.4D). Histology confirmed that these tumors arose from the smooth muscle layer of the uterus 
and consisted of whorled fascicles of fusiform smooth muscle cells with an abundance of 
eosinophilic cytoplasm and ECM deposits (Figure 3.4B, C, E, F), consistent with the pathology 
seen in human uterine leiomyomas. Large tumors were often necrotic, hemorrhagic, and fibrotic. 
In addition, characteristic of leiomyomas, all tumors stained positive for smooth muscle actin 
and showed an abundance of collagen deposits when stained with Masson’s Trichrome stain 
(Figure 3.5A, B). These tumors also expressed estrogen receptor ER-α. (Figure 3.5C), supporting 
our hypothesis that leiomyomas are hormone dependent for their growth (248).  
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Figure 3.3. Histological evaluation of uteri from nulliparous Med12fl/+ Med12Rmt/+Amhr2-cre females 
Control animals (Med12fl/+ Med12Rmt/+) at each time point show normal uterine histology (A,C,G,K) ; a magnified 
view of the white box shows normal endometrial stroma (ES) and myometrium (MY) in (E,I,M). (B) Pathological 
changes associated with leiomyomas begin as early as 8 weeks of age in the uteri expressing Med12 c.131G>A 
variant on the background of conditional loss of Med12 (Med12fl/+ Med12Rmt/+Amhr2-cre). These uteri often display 
characteristic patterns of leiomyoma development, with the presence of ECM deposits and the appearance of 
dispersed nuclei. Evaluation of uteri at (D,F)12 week, (H,J) 16 week and at (L,N) 24 weeks of age display 
leiomyoma-like lesions with features including hyperplasia, fibrosis, ECM deposits and disrupted smooth muscle 
fibers. The white dotted lines in (D,H,L) outline leiomyomas. (O) Representative of hyperplasia, mutant uteri 
weights were higher at 24 weeks than controls ***(p <0.001).  
Data are presented as mean ± SEM. LM-leiomyoma; ES-endometrial stroma; MY-myometrium; EM-endometrium. 
Scale bars = 0.5μm (C,D,G,H,K,L), 100μm (A,B,E,F,M,N), 50μm (I,J). 
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Figure 3.4.   Multiparous Med12fl/+ Med12Rmt/+Amhr2-cre females develop spectacular leiomyoma-like lesions 
similar to human leiomyomas 
(A) 18-week multiparous Med12fl/+ Med12Rmt/+ Amhr2-cre reveals a 4-mm tumorous lesion (white dotted lines). (B)
Histological examination confirms the presence of a large leiomyoma nodule growing from the smooth muscle layer
of the uterus. A higher magnification of the black boxed neoplastic area appears in (C), showing the presence of
fascicles with plump spindle cells, eosinophilic cytoplasm and ECM deposits. (D) 24-week-old Med12fl/+
Med12Rmt/+ Amhr2-cre multiparous female exhibiting multiple nodules (white arrows). (E) Multiple leiomyoma
nodules are outlined by black dotted lines, the black box, shown at higher magnification in (F), highlighting fibrosis
and ECM deposition. About 80% (8/10 females) exhibited leiomyoma-like lesions and hyperplasia. LM-
Leiomyoma; ES-Endometrial stroma; MY-Myometrium. Scale bars = 2000µm (A,D), 1000µm(B), 500µm
(E),100µm (F), 50 µm(C).
Figure 3.5. Molecular characterization of leiomyoma-like lesions 
(A) Representative image from Med12fl/+ Med12Rmt/+ Amhr2-cre uteri, showing immunoreactivity to anti-SMA
antibodies and staining with Masson’s Trichrome. Anti-SMA antibodies show immunoreactivity (brown) in the
leiomyoma-like lesion (LM) outlined with a dotted black line. SMA is a marker for smooth muscle cells.  (B)
Collagen deposits within the uterine tumors stain blue with Masson’s Trichrome (B). Red stains show muscle fibers;
the blue stain indicates an abundance of collagen deposition in the tumor lesion, a known characteristic of
leiomyomas. Med12fl/+ Med12Rmt/+ Amhr2-cre uteri also stain positive for ER-α. ES- endometrial stroma; MY- 
myometrium; E- endometrium bars = 0.2μm (A), 100μm (B, C).
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We also generated more complex mouse models to determine increasing the expression of 
mutant Med12 and diminishing the expression of WT Med12 would result in different 
phenotypic effects from the above-described outcomes. We generated and analyzed the uterine 
histology of 16-week Med12fl/fl Med12Rmt/+ Amhr2-cre (n=4) and Med12fl/fl Med12Rmt/mt Amhr2-
cre (n=1). We were only able to analyze one female of the Med12fl/fl Med12Rmt/mt Amhr2-cre 
genotype, as the frequency of females born with this genotype was very low. The uteri of 16-
week nulliparous Med12fl/fl Med12Rmt/+ Amhr2-cre (Figure 3.6 C, F) and Med12fl/fl Med12Rmt/mt 
Amhr2-cre females were analyzed and found to have a phenotype (Figure 3.6 I, K) similar to that 
of Med12fl/+ Med12Rmt/+ Amhr2-cre females with the appearance of dispersed smooth muscle 
cells interspersed with ECM deposits leading to fibrosis. As reviewed in Chapter 2, Med12fl/fl
Amhr2-cre females are infertile. Interestingly, the Med12fl/fl Med12Rmt/+ Amhr2-cre females were 
also infertile and therefore we could only analyze the uteri of nulliparous females.  However, a 
remarkable observation was that the Med12fl/fl Med12Rmt/+ Amhr2-cre uteri often had hyperplasia 
with uterine weights 50-60% higher than that of Med12fl/fl Amhr2-cre uteri (p<0.05) (Figure 3.6 
G). This suggested that the mutant Med12 expression could rescue the histology but not the 
fertility-related function of WT X-chromosome Med12.  These results indicate that the Med12 
c.131G>A variant causes leiomyoma-like lesions in mice in a dominant manner, and probably
acts via gain of function mechanism with a novel gene function. 
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Figure 3.6. Histological evaluation of uteri from Med12fl/fl Med12Rmt/+ Amhr2-cre, Med12fl/fl Amhr2-cre and 
Med12fl/fl Med12Rmt/mt Amhr2-cre females 
(A) 16-week Control animals (Med12fl/fl Med12Rmt/+) show normal uterine histology; a magnified view of the white
box shows normal endometrial stroma (ES) and myometrium (MY) in (D). (B) Med12fl/fl Amhr2-cre mice
generated on the C57/B6/129Sv/FVB background show hypotrophic uteri, similar to that of Med12fl/fl Amhr2-cre
mice generated on the C57/B6/129Sv background. (C) The uterine histology of Med12fl/fl Med12Rmt/+ Amhr2-cre
mice on the contrary shows hyperplasia with greater myometrial thickness and ECM deposits as observed in (F),
compared to the myometrium of Med12fl/fl Amhr2-cre mice in (E). (G) This difference is quantified by uterine
weights shown in (G) where the uterine weights of Med12fl/fl Amhr2-cre mice are 50% than that of controls; whereas
the uterine weights of Med12fl/fl Med12Rmt/+ Amhr2-cre females is cumulatively 50% greater than that of control and
Med12fl/fl Amhr2-cre mice (p<0.005). (H) Uterine histology of nulliparous 16-week Med12fl/fl Med12Rmt/mt female
with normal uterine histology with the outlined white box shown at a higher magnification in (J). (I) Uterine
histology of 16-week nulliparous Med12fl/fl Med12Rmt/mt Amhr2-cre females displaying the presence of leiomyoma-
like lesions with the presence of ECM deposits and dispersed pattern of nuclei. Higher magnification of the outlined
white dotted lines is shown in (K) where we observe a leiomyoma-like lesion. Error bars represent mean ±S.E.M.
Asterisk indicates significance using ANOVA test where **p<0.005. LM-leiomyoma; ES-endometrial stroma; MY-
myometrium; EM-endometrium. Scale bars = 0.5μm (A,B,C,H,I), 100μm (D,E,F,J,K).
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3.3.3 Med12 c.131G>A variant can cause uterine leiomyomas on WT background 
We investigated if leiomyoma-like lesions were also present when Med12 c.131G>A variant was 
expressed on the WT background (Figure 3.1B). To accomplish this, we generated animals that 
express mutant Med12 from an autosomal locus in the presence of wild-type Med12 expressing 
from the X chromosome (Med12Rmt/+ Amhr2-cre) by crossing Med12Rmt/mt and Amhr2-cre mice 
(Figure 3.1B, 3.2D). Uteri from nulliparous Med12Rmt/+ Amhr2-cre and control mice 
(Med12Rmt/+) were examined at 8, 12, 16, 24, and 32 weeks of age, and subjected to 
histomorphological evaluation. At 8 weeks of age, no leiomyoma-like lesions were observed in 
Med12Rmt/+ Amhr2-cre females (Figure. 3.7 B). Beyond 12 weeks of age, in addition to 
hyperplasia, we observed leiomyomas in 50% of Med12Rmt/+ Amhr2-cre mutant uteri, which 
were characterized by ECM deposits and disorganized pattern of smooth muscle fiber 
arrangement (Figure 3.7D-R). No such abnormalities were observed in control nulliparous 
females (Med12Rmt/+) at any time point (Figure. 3.7 C-Q). Uteri that expressed mutant Med12 
weighed 20-30% more than control uteri with statistical significance (P<0.05) (Figure 3.7S). 
Similar to the previous model, multiparous Med12Rmt/+ Amhr2-cre females revealed nodules that 
histologically resembled human leiomyomas due to deposition of ECM and, whorl formation 
and, with fewer nuclei present (Figure 3.8B, D). We assessed the uterine histology of both 
nulliparous and multiparous Med12Rmt/mt Amhr2-cre females (n=4, per group)  to explore 
whether the expression of homozygous Med12 variant on a WT background would adversely 
affect the phenotypic outcome. The uterine histology of 16 week Med12Rmt/mt Amhr2-cre 
revealed no significant differences from the uterine histology (Figure 3.9 B,D,E,G,I) of 
Med12Rmt/+ Amhr2-cre females of the same age, both with presentation of disrupted smooth 
muscle fibers interspersed with ECM deposits. These results further reinforce the hypothesis that 
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the Med12 variant causes leiomyomas in a dominant fashion. In contrast to the previous model, 
where Med12 c.131G>A variant was 80% penetrant when expressed on the conditional knockout 
background (Med12fl/+ Med12Rmt/+ Amhr2-cre), the penetrance for leiomyomatous formation of 
Med12 c.131G>A variant on WT background was 50%. Moreover, we never observed large 
leiomyoma-like lesions in Med12Rmt/+Amhr2-cre females as we did in Med12fl/+ Med12Rmt/+ 
Amhr2-cre mice (Figure 3.4). Our results show that the Med12 missense variant c.131G>A 
causes uterine hyperplasia and leiomyomas in the background of both wild type X chromosomes 
or conditional Med12 knockout.  In the background of conditional Med12 deletion, leiomyoma-
like lesions tend to have earlier onset and achieved greater size.  Med12 missense variant 
c.131G>A variant therefore acts as a gain of function mutation.
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Figure 3.7. Histological evaluation of uteri from nulliparous Med12Rmt/+Amhr2-cre females 
Control animals (Med12Rmt/+) at each time point show normal uterine histology (A,C,G,K,O) ; a magnified view of 
the white box shows normal endometrial stroma (ES) and myometrium (MY) in (E,I,M,Q). (B) 8 week old 
Med12Rmt/+Amhr2-cre mice do not show any distinct pathological changes associated with leiomyoma formation. 
The uteri of Med12Rmt/+Amhr2-cre females begin to show ECM deposits and dispersed muscle fibers associated 
with leiomyomas at (D, F) 12-weeks of age. These changes progressively increase with age as observed at (H, J) 16 
weeks, (L, N) 24 weeks of age and ultimately give rise to large fibrotic leiomyoma-like lesions as observed at (P,R) 
32 weeks of age. The white dotted lines outline leiomyomas IN (F,P) or magnified areas (D,H,L). (S) Representative 
of hyperplasia, mutant uterine weights were higher at all ages examined as compared to the controls *(p <0.01).  
Data are presented as mean ± SEM. LM-leiomyoma; ES-endometrial stroma; MY-myometrium; EM-endometrium. 
Scale bars = 2000μm (L,P) 0.5μm (A,B,C,D,G,H,K,O), 100μm (E,F,M,Q), 50μm (I,J,N,R). 
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Figure 3.8 Multiparous Med12Rmt/+ Amhr2-cre uteri develop prominent leiomyomas 
(A, C) Uteri from control mice, Med12Rmt/+, that, in the absence of Amhr2-cre, do not express Med12 
c.131G>A variant and show normal cross-sectional histology. (B, D) Uteri of Med12Rmt/+ Amhr2-cre mice
that express the Med12 c.131G>A variant and reveal leiomyoma-like lesions in ~47% females, with typical
sparse nuclear arrangement, nodular pattern of cellular growth, and ECM deposition (black dotted lines)
LM-Leiomyoma; ES-Endometrial stroma; MY-Myometrium; EM-Endometrium. Scale bars = 500μm
(A,B), 100μm (C,D).
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Figure 3.9 Histological evaluation of uteri from nulliparous and multiparous Med12Rmt/mtAmhr2-cre females 
(A, C) Uteri from control mice, Med12Rmt/mt, that, in the absence of Amhr2-cre, do not express Med12 c.131G>A 
variant and show normal histology. (B, D) 16-week uteri expressing homozygous Med12 c.131G>A variant,  
(Med12Rmt/mtAmhr2-cre) develop leiomyoma-like lesions as observed by the presence of ECM deposits and 
disorganized pattern of nuclei. The incidence and presentation of leiomyomas in the uteri of Med12Rmt/mtAmhr2-cre 
females was very similar to that of Med12Rmt/+Amhr2-cre females. (E) Representative of hyperplasia, mutant uteri 
weights was higher in mutant uteri as compared to controls (p <0.01). (G,I)  Multiparous Med12Rmt/mtAmhr2-cre 
uteri also develop prominent leiomyomas as previously observed in the uteri of multiparous Med12Rmt/+Amhr2-cre 
females. The white dotted lines outline the leiomyoma-like lesions. Data are presented as mean ± SEM. LM-
Leiomyoma; ES-Endometrial stroma; MY-Myometrium; EM-Endometrium. Scale bars = 500μm (A,B,F,G), 100μm 
(C,D,H,I). 
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3.3.4 Med12 mouse mutations and genomic instability 
To understand the underlying mechanisms of mutated Med12 driven tumor development, we 
investigated the genomic landscape of the mouse tumors by performing array comparative 
genomic hybridization (aCGH) on four uteri with leiomyoma-like lesions (Med12fl/+Med12Rmt/+ 
Amhr2-cre) and compared them to uteri from littermate controls without Amhr2-cre 
(Med12fl/+Med12Rmt/+). Aberrations were called as deletions or duplications based on the 
logarithmic values of probe signal intensities as shown in Table 3.1.  
Table 3.1 Table of logarithmic signal intensity ratios to interpret aCGH data 
Log ratios Deletion Duplication 
0/2( -ξ) homozygous 
1/2 (-1) heterozygous 
3/2 (0.58) heterozygous 
4/2 (1) homozygous 
>1 Amplification 
The log ratios, which were not whole numbers, such as ±0.3 or ±1.25, were considered as 
mosaic aberrations. The tumors from each of the four uteri showed a range of chromosomal 
abnormalities (approximately 40 abnormalities per tumor), with chromosomes 2, 7, 14 and 17 
being most frequently affected (Figure 3.10A). An example of a deletion and duplication seen in 
the tumors is shown in Figure 3.10B. Genes in these regions were carefully annotated, 
eliminating common CNVs present in the Welcome Sanger Trust database. The affected regions 
often consisted of genes targeting cell cycle checkpoints or common tumor signaling pathways 
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such as Ras, Wnt/β-catenin, Tp53/Rb, NF-kappaβ, and Tgfβ signaling. The complete list of 
aberrations in the uteri of Med12fl/+Med12Rmt/+ Amhr2-cre females is shown in Appendix Table 
5.2. Microarray analysis on genomic DNA from Med12fl/+Med12Rmt/+ Amhr2-cre uteri 
additionally showed a few affected genomic regions with a pattern consistent with focal 
chromothripsis-like alterations (180) (Figure 3.10C). Chromothripsis has been previously 
described by Mehine et al in human uterine leiomyomas as well (178). 
We also mapped these aberrations to the human genome (hg19) to determine regions of 
synteny between mouse and human chromosomes. Approximately 50% of the mouse aberrations 
had syntenic counterparts on human chromosomes (Appendix Table 5.3), and a number of these 
regions are known to be rearranged in human leiomyomas (Table 3.2). For example, mouse 
chromosome locus 17qA3.3, duplicated in Med12fl/+Med12Rmt/+ Amhr2-cre uteri (Figure 3.11A), 
maps to the human 6p21 locus. Similarly, in another Med12fl/+Med12Rmt/+ Amhr2-cre uterus, a 
deletion of the 4qD2.3 locus is syntenic to the human 1p36.1-p35 region (Figure 3.11B). 
Genomic rearrangements in 6p21 and 1p36.1-p35 are common in human leiomyomas. These 
results suggest that Med12 exon 2 mutations are precursors to genomic rearrangements and 
therefore can lead to an unstable genome and which drives tumor progression.  
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Figure 3.10 Representative array profiles of Med12fl/+Med12Rmt/+ Amhr2-cre tumors 
(A) Representative genomic view of  a Med12fl/+Med12Rmt/+ Amhr2-cre tumor showing 19 mouse chromosomes on
the left and the log of signal intensity ratios on the right. We observe numerous deletions (Red arrows) and
duplications (black arrows) throughout the genome of this tumor. (B) Representative example of mosaic gain
followed by a loss of region 18qA1 (chr18: 8457226- 10017847). This region of approximately 345 kb encompasses
the genes Fzd8, Ccny, Cetn1, Thoc1, Usp14, and Colec12. (C) Chromosome view of mouse chromosome 14 of
Med12fl/+ Med12Rmt/+ Amhr2-cre uteri showing chromothripsis.
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Figure 3.11 Representation of human syntenic mapping of uterine rearrangements in mouse Med12fl/+
Med12Rmt/+ Amhr2-cre females  
(A) Genomic duplication observed on mouse chromosome locus 17qA3.3 is syntenic to the human 6p21 locus,
shown in blue. Representative array profile of the 17qA3.3 region, highlighting the 450 kb duplication (chr17:
30586287- 31049473), is also shown. (B) Genomic deletion observed on mouse 4qD2.3 locus is syntenic to the
human chromosome locus 1p36.1-p35. The mouse deletion encompasses 137 kb and is shown in the respective array
profile (chr4: 132799884-132936192). Positions are displayed approximately to scale according to the hg19 and
mm9 physical maps, respectively.
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Table 3.2 Regions shared between human and mouse leiomyomas 
Med12fl/+ Med12Rmt/+ Amhr2-cre uteri chromosomal aberrations and corresponding human syntenic 
regions implicated in human leiomyomas. 
3.3.5  Expression of mutant Med12 in myometrial cells using the Myosin heavy chain 11- 
cre (Myh11-cre) 
We had shown earlier in Chapter 2 that the Amhr2-cre recombination efficiency was 
approximately 50%.  We also wanted to investigate the penetrance and the effects of mutant 
Med12 expression on the phenotype and the penetrance of the Med12 Rosa knock-in model by 
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using another smooth muscle specific-cre. We chose to use Myosin heavy chain 11 driven Cre 
that is expressed in all smooth muscle tissues, including the uterine myometrium starting at 
E13.5 (249). We generated the Med12Rmt/+ Myh11-cre by crossing Med12Rmt/mt and Myh11-cre 
mice and evaluated the uterine histology and morphology at 12 weeks of age. The histological 
presentation of   Med12Rmt/+ Myh11-cre was not dramatically different from that of Med12Rmt/+ 
Amhr2-cre uteri, with the presence of ECM deposits and disorganized smooth muscle fibers 
(Figure 3.12 B, D). This suggested to us that the phenotype and the penetrance observed in the 
previous models was independent of the type of specific smooth muscle cre allele used to 
recombine the floxed sites. 
Figure 3.12 Evaluation of 12-week Med12Rmt/+ Myh11-cre uteri 
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(A,C) 12-week control animals (Med12Rmt/+) show normal uterine histology. (B) 12-week Med12Rmt/+ Myh11-
cre shows the development of leiomyoma-like lesions with the outlined white dotted box shown at a higher 
magnification in (D) highlighting the dispersed pattern of nuclei and ECM deposits (white dotted lines). The 
size or the presentation of lesions in Med12Rmt/+ Myh11-cre did not differ from that of 12-week old Med12Rmt/+ 
Amhr2-cre females. Scale bars=0.5μm (A,B), 100μm (C,D). 
3.4 DISCUSSION 
Recurrent human MED12 exon 2 mutations have been associated with benign tumors such as 
uterine leiomyomas (161), breast fibroadenomas (186) and phyllodes tumors (187, 190); 
however, their etiology, genetic mechanism of action, and role in genomic instability are 
unknown. To study the role of Med12 mutations in uterine leiomyomas, we generated a mouse 
model which would conditionally express the most common human Med12 c.131G>A variant 
from the autosomal ROSA26 locus and allow us to study its effects in a tissue-specific manner in 
the uterus. Our strategy allowed us flexibility, to develop mouse models where mutated Med12 
was expressed either in the absence (gain of function) or presence (dominant negative) of X-
chromosome WT Med12. We found that expression of mutated Med12 in the absence or 
presence of X-chromosome Med12 gave rise to leiomyoma-like lesions, regardless of the 
background, although the age of onset and the presentation of leiomyomas were different 
between the two models. Remarkably, the mouse leiomyomas shared histological features of 
human uterine leiomyomas.  
Parity appeared to have an adverse effect on leiomyomatous growth, as multiparous 
females in both models presented with the larger and more distinct leiomyoma-like lesions as 
compared to nulliparous females. This may be explained by the exposure of the Med12 mutated 
uterus, to a milieu of steroid hormones during pregnancy, therefore driving growth of 
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leiomyomas. This finding is in agreement with human data, as reports have suggested that 
pregnancy often has dramatic effects on human fibroids (45). 
In comparison to the dominant negative model, leiomyoma-like lesions in the gain-of-
function model were often larger, more penetrant, and presented as early as 8-weeks of age. 
These findings suggest that the Med12 c.131G>A variant alone drives tumor formations via gain-
of-function mechanism. 
We also examined the phenotypes of animals expressing homozygous mutant Med12 
c.131G>A variant, on a background of Med12 cKO (Med12fl/fl) mice (Med12fl/fl Med12Rmt/+ 
Amhr2-cre and Med12fl/fl Med12Rmt/mt Amhr2-cre). Although the penetrance and the size of 
leiomyoma-like lesions was similar to the previous models (Med12fl/fl Med12Rmt/+ Amhr2-cre and 
Med12Rmt/+ Amhr2-cre), yet the expression of the mutant Med12 was able to rescue the histology 
of the Med12fl/fl Amhr2-cre (Med12 cKO) uteri as observed by the heavier uterine weights of 
Med12fl/fl Med12Rmt/+ Amhr2-cre females. The fact that the Med12fl/fl Med12Rmt/+ Amhr2-cre 
females still remain infertile indicates that the mutant Med12 may have a role distinct of the X-
chromosome Med12 (neomorph). A caveat applies to the models on the background of Med12 
cKO as the tumorigenic changes occurring have to be evaluated against a hypoplastic 
background, making data interpretation difficult. 
There are three published transgenic mouse models of uterine leiomyomas; these include 
transgenic overexpression of hGPR10-driven with calbindin-D9K promoter (227), conditional 
deletion of Tsc2 (224), and conditional expression of a gain-of-function mutant form of β-catenin 
(225). The phenotype in these mice is confined to increased myometrial thickness and formation 
of small nodules, but none show the dramatic tumors we report here (Figure 3.4). Interestingly, 
Amhr2-cre drives mutant Med12 expression in both uterine smooth muscle tissue (myometrium) 
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and stroma, yet we only observed tumors deriving from the mouse myometrium. In contrast, 
Amhr2-cre–driven expression of the gain-of-function mutant form of β-catenin causes tumors 
both in the mouse myometrium and in the stroma (225). These results indicate that Med12 exon 
2 mutations have specific tumorigenic effects in smooth muscle cells. 
 Studies published on human leiomyomas were unable to establish a correlation between 
MED12 positive leiomyomas and underlying cytogenetic changes, which are often observed in 
about 40% of human leiomyomas. We utilized our mouse models to explore this further. Array 
CGH on Med12 c.131G>A mouse uteri revealed genome-wide aberrations affecting regions 
containing genes belonging to a variety of tumor pathways including Ras, Wnt/β-catenin, 
Tp53/Rb, NF-kappaβ, and Tgfβ signaling. We also observed complex chromosomal alterations 
such as chromothripsis. Recently, chromothripsis was reported in human leiomyomas and 
proposed as a possible mechanism of tumor progression (91). This suggests a role of Med12 as a 
global transcriptional regulator and guardian of genome integrity.  
 Another key feature of the mouse leiomyomas, is that some of the chromosomal 
aberrations occurring in these regions, also occur in regions syntenic to human 1p, 1q, 2q, 6p21, 
and 18p loci. It was previously shown that 60% of human leiomyomas with 6p21 rearrangements 
harbored MED12 exon 2 mutations (163).  
 Previous reports had suggested that the MED12 exon 2 mutations uncouple Cyclin C–
CDK8/19 interface leading to diminished CDK8 activity (250). Interestingly, in our array data 
we did not observe any changes in Cdk8, Cyclin C, Med13 or Cdk19, rather we observed more 
global genome-wide changes. The CDK8 and MED12 studies were conducted on baculovirus 
systems (in-vitro) whereas our mechanistic studies were conducted on in-vivo mouse models 
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making it evolutionarily more relevant to the role of human MED12 exon 2 mutations in 
tumorigenesis. 
Overall, we have successfully created the first animal models for uterine leiomyomas 
harboring Med12 exon 2 mutations. This model will be a valuable tool not only to understand the 
genesis of uterine leiomyomas but also other steroid influenced tumors such as breast 
fibroadenomas, and phyllodes tumors, as well. These models will also provide a platform to test 
therapeutic targets to treat uterine leiomyomas as an alternative to hysterectomy. 
The limitations of our model include regulatory differences that may exist in the 
expression of Med12 on the X chromosome versus an autosome. The autosomal Med12 is under 
the control of ROSA promoter, which probably differs from the native Med12 promoter. In 
addition to the model itself, factors such as random X-chromosome inactivation influencing the 
Med12 floxed allele expression and Amhr2-cre mediated allelic recombination add to the 
complexities of this study. Nonetheless, we have successfully created the first animal model for 
uterine leiomyomas and Med12 exon 2 mutations. Our model mimics the human condition and 
shows that Med12 variants can act through a gain-of-function mechanism.  
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4.0  OVERALL SUMMARY AND CONCLUSIONS 
Ever since studies first associated MED12 exon 2 variants with human uterine leiomyomas (159) 
(161), numerous studies have replicated the association of MED12 exon 2 variants with 
leiomyomas from women of ethnically diverse backgrounds. The MED12 exon 2 variant studies 
have now been extended to many different types of benign and malignant tumors . Since its 
discovery using whole exome sequencing, MED12 exon 2 variants have been classified as the 
most frequently occurring variants associated with gynecological tumors. 
Over the years, many groups have speculated on the possible mechanisms of MED12 
exon 2 variants in tumor causation, but such mechanisms are difficult to study in vivo in human 
tissues. Animal models expressing and analyzing in-vivo functions of Med12 exon 2 variants 
have been lacking. Our own observations of the MED12 exon 2 variants in the mixed North 
American women population convinced us of the importance of this gene in leiomyoma biology. 
The high frequency of MED12 mutations in leiomyomas, clustering of the mutations in an 
evolutionary conserved region of the gene, and its location on the X-chromosome made MED12 
an ideal candidate gene for generating animal models and studying its role in tumorigenesis. 
The overarching goal of my thesis work was to investigate the role of MED12 exon 2 
variants, in leiomyoma initiation and to determine the role of MED12 in normal uterine function.  
As the Med12 gene is highly conserved between humans and mice, it gave us the 
opportunity to model this gene in-vivo using mouse models. As typical of modeling any driver 
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mutations in tumors (example: p53) (245), we chose to generate loss of function, gain of function 
and dominant negative models of Med12 exon 2 variants. The first of this thesis entailed 
characterization of Med12 cKO females (loss of function) using the Med12flox (220) and Amhr2-
cre (226) mice. Loss of function did not stimulate leiomyomas. On the contrary, Med12 cKO 
females appeared to have hypoplastic uteri, and were infertile. Although, young Med12 cKO 
ovaries were capable of ovulating under external gonadotropic stimulus, adult Med12 cKO 
ovaries lacked large follicles and had the appearance of hyperchromatic “follicular nests”. Such 
structures have also been reported in the ovaries of mutant beta-catenin females (225) (239). The 
global phenotype observed in the reproductive tracts of the Med12 cKO female point towards a 
defect in estrogen and progesterone synthesis. It is possible that either Med12 directly or 
indirectly targets steroid hormones and their receptors, or simply, the loss of granulosa cells in 
Med12 cKO ovaries may result in reduced steroid hormone synthesis. Based on the phenotypic 
similarities between beta-catenin cKO (239) (225) and Med12 cKO reproductive tracts, one 
could infer that loss of beta-catenin may in part contribute to the infertility phenotype. In the 
future, experiments aimed to assay serum estrogen, progesterone levels, cumulus cell expansion, 
fertilization potential, uterine implantation and decidualization will be important to determine the 
cause of infertility. In addition, determining the expression of beta-catenin and hormone 
receptors will also be important. As part of this aim, I also synthesized a new Med12 antibody to 
quantitate Med12 expression and localization. In addition to protein expression studies, this 
antibody will be a valuable resource to conduct experiments such as IP and ChIP-seq. 
Alternatively, the FLAG reporter fused to Med12 cDNA at the ROSA locus may also be used to 
conduct ChIP-seq experiments. Thus, data from our loss of function mouse model indicates that 
loss of Med12 is not the likely mechanism of Med12 exon 2 variants for leiomyomagenesis, 
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contrary to previous reports based on in-vitro data (250). This model will be a useful tool to help 
understand the function of MED12 in uterine biology and pregnancy. 
To examine the gain of function or dominant negative effects of Med12, we developed 
the conditionally floxed Med12 ROSA knock in mouse model, giving us the opportunity to 
express mutated Med12 from the ROSA locus, either in the absence (gain-of-function) or in the 
presence of X-chromosome wild-type Med12. Thus, the latter half of my thesis focused on 
developing and characterizing various genotypes associated with the gain of function and 
dominant negative mouse models. We remarkably observed leiomyoma-like lesions, in about 
87% of females expressing mutated Med12 in the absence of wild-type Med12 and in about 50% 
of females expressing mutated Med12 in the presence of wild-type Med12, showing that Med12 
c.131G>A alone can cause leiomyomas in a dominant manner. As concomitant deletion of 
Med12 did not ameliorate the phenotype of Med12 knock in mice, but made it worse, we 
conclude that the c.131G>A mutation represents a gain of new function (neomorph) rather than a 
gain of existing function (hypermorph) (248). In both the models, appearance of the most distinct 
leiomyomas was observed in multiparous females, suggesting a role of Med12 in steroid driven 
leiomyomagenesis. This may also explain the presence of recurrent MED12 exon 2 variants in 
other steroid driven tumors such as fibroadenomas (186) and phyllodes tumors (187) of the 
breasts. Our data indicates a link between Med12, steroidogenesis, infertility and tumorigenesis. 
In the future, these models could be used to decipher the specific roles of estrogen and 
progesterone in tumor initiation and progression by performing ovariectomy followed by 
estrogen and progesterone supplementation. Testing gonadotropic antagonists on the Med12 gain 
of function models might be another way to examine their individual roles in tumorigenesis.  
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Not only did the Med12 exon 2 variants cause leiomyomas, they also led to genomic 
instability in the leiomyomas. Moreover, the genomic instability outcomes affected several 
pathways, therefore reflecting the role of MED12 as a global regulator of genome stability (204). 
In the future, it is crucial to determine the specific targets of the exon 2 variants through RNA-
seq or ChIPseq, to help design small molecule inhibitors that will modulate the activity of 
pathways associated with MED12 mutated leiomyomagenesis. Interestingly, several regions 
previously implicated in human leiomyomas were also shared by the mouse leiomyomas, 
revealing the similarities between human and mouse leiomyomas. This data suggests that Med12 
exon 2 mutations are precursors to genomic rearrangements and hence can cause an unstable 
genome and drive tumor progression. The results from this thesis collectively provide novel 
insights into the mechanism of Med12 exon 2 variants in leiomyoma causation, and also 
establish a unique link between Med12, steroidogenesis and fertility. Deciphering the functions 
of Med12 from the loss of function mouse model may be a means to further understand the roles 
of Med12 in tumorigenesis.  
Although there are limitations to our model as explained in section 3.4, we have 
successfully generated a novel model for leiomyomas which successfully replicates the human 
condition with shared pathological and cytogenetic features between mouse and human 
leiomyomas. These models will also serve as a platform to help identify drug targets to develop 
and test small molecule therapeutics, to move the field of leiomyoma research forward. Further, 
these models will help us in understanding the mechanism of Med12 exon 2 variants in other 
benign tumors such as fibroadenomas and phyllodes tumors of the breasts. 
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APPENDIX: ABBREVIATIONS AND TABLES 
Table 4.1 List of abbreviations 
bFGF                  basic fibroblast growth factor 
BHD          Birt-Hogg-Dubé syndrome 
bp           base pair 
BRAF             v-raf murine sarcoma viral oncogene homolog
C                  cytosine 
cDNA                  complementary deoxyribonucleic acid 
CDK19                cyclin-dependent kinase 19 
CDK8                  cyclin-dependent kinase 8 
CUX1                  cut-like homeobox 1 
D          aspartic acid 
DNA                  deoxyribonucleic acid 
DAPI           4’,6- Diamidino-2-2phenylindole, Dihydrochloride 
G                Glutamine 
ECM                  extracellular matrix 
 ER                 estrogen receptor 
FH                  fumarate hydratase 
G                guanine 
 HE         hematoxylin-eosin 
HLRCC                   hereditary leiomyomatosis and renal cell cancer 
HMGA            high mobility group A 
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HMGA1                high mobility group AT-hook 1 
 HMGA2   high mobility group AT-hook 2 
hCG    human chorionic gonadotropin 
IGF             insulin-like growth factor ins insertion 
IP       intra peritoneum 
IU          International Unit 
KAT6B         K(lysine) acetyltransferase 6B 
let-7               lethal-7 
LOH     loss of heterozygosity 
LS     leucine-serine-rich 
MED12           Mediator complex subunit 12 
MED12L                Mediator complex subunit 12-like 
 MED13      Mediator complex subunit 13 
 MED13L             Mediator complex subunit 13-like 
MIM            Mendelian Inheritance in Man 
MRI                magnetic resonance imaging 
p           short arm of a chromosome 
PCR                 polymerase chain reaction 
PMSG          Pregnyl mare serum gonadotropin 
Pol II       RNA polymerase II 
PR     Progesterone receptor 
q     long arm of a chromosome 
RAD51B     RAD51 paralog B 
RAS       rat sarcoma RB1 retinoblastoma 1 
RB1             retinoblastoma 1 
REST     RE1-silencing transcription factor 
RNA               ribonucleic acid 
 Table 4.1 continued
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SNP  single-nucleotide polymorphism 
 t     translocation 
TCA    tricarboxylic acid cycle 
TGF-β             transforming growth factor beta 
TP53      tumor protein 53 
TSC         tuberous sclerosis 
TSC2   tuberous sclerosis 2 
VEGF             vascular endothelial growth factor 
WHO   the World Health Organization 
WNT4         wingless-type MMTV integration site family, member 4 
Table 4.1 continued
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Table 4.2 Regions of aberrations in mouse leiomyomas 
Chr Cytoband Start Stop 
Aberration size 
(Kb) Gain/Loss Region of Aberration 
chr1 qD 90115633 90193738 78.105 deletion 3 
chr1 qE1.1 101591968 101656500 64.532 gain 1 
chr1 qH4 179805696 179926632 120.936 deletion 1 
chr1 qH5 187079059 187183640 104.581 gain 1 
chr2 qA1 3947206 4016684 69.478 deletion 3 
chr2 qC1.3 62554677 62580394 25.717 deletion 4 
chr2 qD 85849412 85920056 70.644 gain 4 
chr2 qH2 161545931 161698753 152.822 gain 1 
chr3 qF1 87188304 87211687 23.383 gain 1 
chr3 qF1 87267733 87302881 35.148 gain 1 
chr3 qF3 110878881 110995945 117.064 gain 1 
chr4 qD1 111726014 113251939 1525.925 deletion 4 
chr4 qD1 111742887 112273763 530.876 deletion 4 
chr4 qD1 111962345 112065411 103.066 deletion 4 
chr4 qD1 112289418 112504314 214.896 deletion 3 
chr4 qD1 112510205 112564300 54.095 deletion 4 
chr4 qD1 112665000 112793116 128.116 deletion 4 
chr4 qD1 112821289 112915923 94.634 deletion 4 
chr4 qD1 113001582 113251939 250.357 deletion 2 
chr4 qD1 113286238 113658273 372.035 deletion 1 
chr4 qD2.2 121649423 122218644 569.221 deletion 1 
chr4 qD2.3 132799884 132936192 136.308 deletion 1 
chr4 qE1 145001092 146793868 1792.776 deletion 3 
chr5 qC3.1 69891606 70097860 206.254 gain 3 
chr5 qE5 105142362 105237345 94.983 gain 1 
chr6 qA1 8556759 8575270 18.511 gain 1 
chr6 qB1 41010073 41112757 102.684 gain 1 
chr6 qB1 41306470 41412425 105.955 gain 2 
chr7 qA2 18382929 18426616 43.687 gain 1 
chr7 qB4 54844755 54883844 39.089 deletion 2 
chr7 qB4 55466579 55715246 248.667 gain 1 
chr7 qC 67475144 67731725 256.581 deletion 1 
chr7 qE3 111430424 111507023 76.599 deletion 1 
chr7 qF1 123631491 123927328 295.837 deletion 2 
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chr7 qF3 136825759 137141925 316.166 gain 1 
chr8 qA1.2 16763830 16826155 62.325 gain 1 
chr8 qA4 40187843 40274870 87.027 gain 1 
chr9 qA3 21968269 22021024 52.755 deletion 1 
chr9 qA5.3 46697499 46906183 208.684 deletion 0 
chr10 qA3 17697339 17744401 47.062 deletion 1 
chr10 qA3 22006887 22072759 65.872 gain 1 
chr12 qE 105048428 105263855 215.427 deletion 2 
chr12 qF1 114886825 114956321 69.496 gain 4 
chr12 qF1 - qF2 115427710 115487987 60.277 deletion 4 
chr12 qF2 115667710 115852666 184.956 gain 4 
chr12 qF2 116155408 116261498 106.09 deletion 4 
chr12 qF2 116515691 116624944 109.253 deletion 4 
chr12 qF2 116840011 117047397 207.386 gain 
chr12 qF2 117198164 117274793 76.629 deletion 
chr13 qA1 12690823 12723384 32.561 Deletion 2 
chr13 qB3 61743712 62048006 304.294 gain 1 
chr13 qC1 75983645 76020728 37.083 Deletion 1 
chr13 qD1 101053361 101110842 57.481 deletion 1 
chr14 qC1 44380406 44579789 199.383 Gain 1 
chr14 qC2 54320774 54422503 101.729 gain 1 
chr14 qD1 69019011 69103662 84.651 gain 1 
chr14 qD2 69209459 69249991 40.532 gain 1 
chr14 qD2 69876584 70090608 214.024 deletion 2 
chr14 qD2 72891034 72930683 39.649 gain 1 
chr14 qD3 84908855 85042415 133.56 gain 1 
chr14 qE1 86407031 86441138 34.107 gain 1 
chr14 qE3 110472070 111123931 651.861 deletion 1 
chr14 qE3 - qE4 110015732 111565569 1549.837 deletion 1 
chr15 qA1 14992022 15100240 108.218 gain 
chr15 qE1 77310653 77364452 53.799 gain 3 
chr16 qB3 35483725 35550180 66.455 gain 1 
chr16 qB3 36245661 36336077 90.416 deletion 1 
chr16 qB4 44819587 44909082 89.495 gain 1 
chr17 qA3.3 30586287 31049473 463.186 gain 4 
chr17 qB1 36199712 36245963 46.251 gain 1 
chr17 qB1 36860348 36909276 48.928 deletion 1 
chr17 qB1 38635045 38791870 156.825 gain 1 
chr17 qB1 - qB2 40082709 40241053 158.344 deletion 4 
chr18 qA1 8457226 9788370 1331.144 gain 1 
chr18 qA1 9813671 10017847 204.176 deletion 3 
Table 4.2 continued
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Chromosomal aberration list of all four-mouse tumors with the interval, number of genes and critical genes in each 
region 
chr19 qD3 60897053 60945155 48.102 Gain 1 
Table 4.2 continued
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Table 4.3 Syntenic regions between mouse aberrations and human chromosomes 





locus Start Stop Tumor 1 Tumor 2 Tumor 3 Tumor 4 





3qF3 chr1 106701046 106830733 - - 
3qF1 chr1 157764252 157772664 FCRL1 












1qH4 chr1 244734347 244817416 
DESI2,CO
X20 
1qE1.1 chr2 124573472 124762072 
2qC1.3 chr2 163236878 163260207 







16qB3 chr3 122738925 122793361 
SEMA5B, 
PDIA5 





8qA4 chr4 190221667 190228149 
13qC1 chr5 95111576 95153221 
RHOBTB3, 
GLRX 
15qA1 chr5 29027869 29199306 
13qD2.
3 chr5 45614983 45626841 HCN1 HCN1 
13qD1 chr5 66052023 66071066 
13qD1 chr5 70265907 70308766 NAIP 
17qA3.











10qA3 chr6 139348580 139403048 ABRACL ABRACL 
6qA1 chr7 8134096 8148036 
6qB1 chr7 142190236 142250584 
8qA4 chr8 15586895 15636766 TUSC3 





14qD2 chr8 24187964 24229697 ADAM28 
14qD1 chr8 24383271 24461193 
14qD2 chr8 36716399 36733668 KCNU1 
8qA1.2 chr8 3989107 4060094 
2qA1 chr10 14283901 14363312 FRMD4A FRMD4A 
18qA1 chr10 35739803 36669673 
CCNY,GJ
D4,FZD8 




7qF3 chr10 122740826 123058528 
2qD chr11 56216083 56241010 SLC25A37 
9qA5.3 chr11 115811243 116008575 KCNU1 
14qD3 chr13 58275467 58409706 PCDH17 
14qE1 chr13 59632641 59660044 
14qE3 
- 





14qE3 chr13 85660155 86345915 
12qE chr14 94879399 94946027 
SERPINA11, 
SERPINA9 
12qF1 chr14 106209967 106242264 
7qF1 chr16 18175137 18325190 
11qB5 chr17 2938562 2948297 
11qB4 chr17 5417772 5463831 NLRP1 









2qH2 chr20 40900568 41046759 PTPRT 
List of human chromosomal intervals that are syntenic to mouse chromosomal aberration intervals and 
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